var title_f2_43_2736="Contents: Pediatric trauma";
var content_f2_43_2736=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric trauma",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric trauma",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Abdominal trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/44/13001\">",
"           Hollow viscus blunt abdominal trauma in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/42/4777\">",
"           Liver, spleen, and pancreas injury in children with blunt abdominal trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/62/33768\">",
"           Overview of blunt abdominal trauma in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Burns",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/10/44201\">",
"           Emergency care of moderate and severe thermal burns in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/19/4410\">",
"           Environmental electrical injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/38/37479\">",
"           Treatment of minor thermal burns",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Child abuse",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/13/32985\">",
"           Child abuse: Epidemiology, mechanisms, and types of abusive head trauma in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/19/40249\">",
"           Child abuse: Evaluation and diagnosis of abusive head trauma in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/7/20602\">",
"           Child abuse: Eye findings in children with abusive head trauma (AHT)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/2/19497\">",
"           Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/30/13802\">",
"           Orthopedic aspects of child abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/19/24890\">",
"           Physical abuse in children: Diagnostic evaluation and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/54/26473\">",
"           Physical abuse in children: Epidemiology and clinical manifestations",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/11/40119\">",
"           Approach to the initially stable child with blunt or penetrating injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/32/12807\">",
"           Chest wall injuries in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/12/7367\">",
"           Classification of trauma in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/30/7658\">",
"           Emergency ultrasound in adults with abdominal and thoracic trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/31/11767\">",
"           Overview of pediatric injury prevention: Epidemiology; history; application",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/53/35669\">",
"           Straddle injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/16/29962\">",
"           Trauma management: Approach to the unstable child",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/25/3477\">",
"           Trauma management: Unique pediatric considerations",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Genitourinary trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/11/35000\">",
"           Scrotal trauma in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Head and neck trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/26/8616\">",
"           Acquired torticollis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/25/41368\">",
"           Approach to the young athlete with neck pain or injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/25/29079\">",
"           Assessment and management of auricular hematoma and cauliflower ear",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/46/32489\">",
"           Evaluation and management of dental injuries in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/29/5593\">",
"           Evaluation and management of middle ear trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/7/32889\">",
"           Evaluation of cervical spine injuries in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/9/4250\">",
"           Initial approach to severe traumatic brain injury in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/35/10808\">",
"           Intracranial epidural hematoma in children: Clinical features, evaluation, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/61/11222\">",
"           Intracranial epidural hematoma in children: Epidemiology, anatomy and pathophysiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/49/29464\">",
"           Intracranial subdural hematoma in children: Clinical features, evaluation, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/4/21575\">",
"           Intracranial subdural hematoma in children: Epidemiology, anatomy, and pathophysiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/29/6615\">",
"           Jaw fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/38/12906\">",
"           Minor head trauma in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/50/33575\">",
"           Nasal trauma and fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/34/8745\">",
"           Open globe injuries: Emergent evaluation and initial management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/35/9783\">",
"           Orbital fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/30/23016\">",
"           Oropharyngeal trauma in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/24/13704\">",
"           Skull fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/53/4951\">",
"           Spinal cord injury without radiographic abnormality (SCIWORA) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/10/38057\">",
"           Traumatic hyphema: Clinical features and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/21/17750\">",
"           Traumatic hyphema: Epidemiology, anatomy, and pathophysiology",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hip",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/42/23209\">",
"           Slipped capital femoral epiphysis (SCFE)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ophthalmologic trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/25/4502\">",
"           Conjunctival injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/8/39045\">",
"           Eyelid lacerations",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Orthopedic trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/49/24345\">",
"           Ankle fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/9/5273\">",
"           Approach to the young athlete with acute knee pain or injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/34/29223\">",
"           Approach to the young athlete with chronic knee pain or injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/36/29251\">",
"           Capitate fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/33/8726\">",
"           Causes of chronic knee pain in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/60/38855\">",
"           Causes of chronic wrist pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/20/31050\">",
"           Clinical features and management of ankle pain in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/41/23190\">",
"           Clinical features and management of foot pain in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/6/28775\">",
"           Clinical features and management of heel pain in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/8/42120\">",
"           Diagnosis and assessment of distal forearm fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/5/7257\">",
"           Distal femoral fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/9/19607\">",
"           Elbow anatomy and radiographic diagnosis of elbow fracture in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/25/22937\">",
"           Elbow injuries in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/8/22663\">",
"           Epicondylar and transphyseal elbow fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/46/19175\">",
"           Evaluation and management of condylar elbow fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/22/25961\">",
"           Evaluation and management of supracondylar fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/23/14711\">",
"           Evaluation of foot and ankle pain in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/43/32440\">",
"           Evaluation of wrist pain and injury in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/52/40776\">",
"           Femoral shaft fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/6/26726\">",
"           Fibular fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/28/15815\">",
"           Field care and evaluation of the young athlete with acute neck injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/26/17828\">",
"           First (thumb) metacarpal fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/16/35079\">",
"           Foot fractures (other than metatarsal or phalangeal) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/40/20104\">",
"           General principles of fracture management: Fracture patterns and description in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/25/9620\">",
"           Hamate fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/14/31975\">",
"           Hip fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/17/4376\">",
"           Initial evaluation and management of rib fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/14/14569\">",
"           Initial management of distal forearm fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/29/6615\">",
"           Jaw fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/61/24531\">",
"           Lunate fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/9/22675\">",
"           Metacarpal base fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/11/22707\">",
"           Metacarpal head fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/4/13382\">",
"           Metacarpal neck fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/5/20565\">",
"           Metacarpal shaft fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/35/14903\">",
"           Metatarsal and toe fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/20/12614\">",
"           Metatarsal shaft fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/21/11609\">",
"           Midshaft forearm fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/13/30934\">",
"           Midshaft humeral fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/50/33575\">",
"           Nasal trauma and fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/35/9783\">",
"           Orbital fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/8/32905\">",
"           Overview of acute wrist injuries in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/49/4886\">",
"           Overview of carpal fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/8/23689\">",
"           Overview of cervical spinal cord and cervical peripheral nerve injuries in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/6/2149\">",
"           Overview of metacarpal fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/49/11033\">",
"           Overview of musculoskeletal neck injuries in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/19/23866\">",
"           Overview of stress fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/53/42838\">",
"           Overview of tibial fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/42/21157\">",
"           Patella fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/0/24581\">",
"           Patellar dislocations in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/22/37218\">",
"           Pisiform fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/54/873\">",
"           Proximal fifth metatarsal fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/29/3546\">",
"           Proximal fractures of the forearm in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/17/24855\">",
"           Proximal humeral fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/51/42807\">",
"           Proximal tibial fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/40/38532\">",
"           Radial head subluxation (nursemaid's elbow)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/51/1848\">",
"           Scaphoid fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/52/28485\">",
"           Sesamoid fractures of the foot",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/24/13704\">",
"           Skull fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/50/43812\">",
"           Stress fractures of the humeral shaft",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/61/33747\">",
"           Stress fractures of the metatarsal shaft",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/4/19527\">",
"           Stress fractures of the tibia and fibula",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/46/24296\">",
"           Tibial and fibular shaft fractures in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/3/36915\">",
"           Trapezium fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/39/33394\">",
"           Trapezoid fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/50/28455\">",
"           Traumatic causes of acute knee pain and injury in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/61/4056\">",
"           Treatment of knee injuries in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/55/36723\">",
"           Triquetral fractures",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thoracic trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/63/27640\">",
"           Initial evaluation and stabilization of children with thoracic trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/26/3495\">",
"           Intrathoracic injuries in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/38/29285\">",
"           Pulmonary contusion in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/53/40793\">",
"           Spontaneous pneumothorax in children",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-F824BE2F25-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f2_43_2736=[""].join("\n");
var outline_f2_43_2736=null;
var title_f2_43_2737="Pain provocation test for SLAP lesion";
var content_f2_43_2737=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1124px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/82888/Pain_provocation_video.mp4?title=Pain+provocation+test+for+SLAP+lesion\" style=\"width:480px;height:288px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pain provocation test for SLAP lesion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To perform the pain provocation test, the patient sits with the examiner standing behind them. The examiner holds the patient&rsquo;s wrist with their ipsilateral hand while the contralateral hand gently braces the patient&rsquo;s shoulder. The shoulder is abducted to 90 to 100 degrees directly to the side with the elbow flexed 90 degrees. The arm is then maximally externally rotated and while maintaining this position the arm is then maximally pronated and supinated. The test is positive if maximal pronation elicits or worsens pain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Simons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_43_2737=[""].join("\n");
var outline_f2_43_2737=null;
var title_f2_43_2738="MRI of reactivated Chagas in the CNS";
var content_f2_43_2738=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI images from an HIV-infected patient with reactivated Chagas disease in the central nervous system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 292px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drs. Marcela Campo and Cesar Arias.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_43_2738=[""].join("\n");
var outline_f2_43_2738=null;
var title_f2_43_2739="Radical vulvectomy2";
var content_f2_43_2739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radical vulvectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The specimen has been dissected laterally and off the symphysis pubis. The suspensory ligament is seen attached to the symphysis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of C. William Helm, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_43_2739=[""].join("\n");
var outline_f2_43_2739=null;
var title_f2_43_2740="Liver biopsy HSTL";
var content_f2_43_2740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Liver biopsy from a patient with hepatosplenic lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 196px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Liver biopsy from a patient with hepatosplenic lymphoma demonstrates infiltration of monotonous, medium-sized lymphoid cells with round or slightly irregular nuclei, loosely condensed chromatin, and a moderate amount of pale cytoplasm. H&amp;E; 1000X.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Kindly provided by German Pihan, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_43_2740=[""].join("\n");
var outline_f2_43_2740=null;
var title_f2_43_2741="Cinacalcet: Patient drug information";
var content_f2_43_2741=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cinacalcet: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"     see \"Cinacalcet: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F151617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sensipar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5062253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sensipar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691892",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high parathyroid hormone levels in dialysis patients.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high calcium levels in patients with parathyroid disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cinacalcet or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697292",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low calcium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698211",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low calcium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698248",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain, back pain, soreness, or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698986",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11704 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-65E6C3AFCD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_43_2741=[""].join("\n");
var outline_f2_43_2741=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151617\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5062253\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021751\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021753\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021752\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021757\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021758\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021760\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021755\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021756\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021761\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021762\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=related_link\">",
"      Cinacalcet: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_43_2742="Sulfadoxine and pyrimethamine: Patient drug information";
var content_f2_43_2742=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sulfadoxine and pyrimethamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=see_link\">",
"     see \"Sulfadoxine and pyrimethamine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/47/8949?source=see_link\">",
"     see \"Sulfadoxine and pyrimethamine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F223844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fansidar&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad rashes have been reported. Talk with your doctor right away if you get a rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor right away about any fever, sore throat, signs of infection, bleeding, shortness or breath, or feeling tired.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691520",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat malaria.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700982",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give this drug to an infant younger than 2 months of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pyrimethamine, sulfadoxine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703168",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have anemia caused by low folic acid stores or porphyria.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant and near term.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Other measures are needed along with this drug including using screens, bed netting, insect repellent (10% to 35% DEET), and permethrin spray on clothing and nets. Avoid spraying most insect repellents on children. Lower evening and night-time outdoor activity.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or planning on getting pregnant, talk with your doctor. You may need even higher doses of folic acid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a pregnant woman and traveling to a malaria infested place, talk to your doctor about the risks first.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia and low platelet count may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever that happens while in or after coming back from the malaria area.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11917 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-F6FDDAB425-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_43_2742=[""].join("\n");
var outline_f2_43_2742=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223844\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022001\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022003\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022002\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022007\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022008\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022010\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022005\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022006\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022011\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022012\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=related_link\">",
"      Sulfadoxine and pyrimethamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/47/8949?source=related_link\">",
"      Sulfadoxine and pyrimethamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_43_2743="Anti-U1 RNP antibodies in mixed connective tissue disease";
var content_f2_43_2743=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anti-U1 RNP antibodies in mixed connective tissue disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/43/2743/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/43/2743/contributors\">",
"     Robert M Bennett, MD, FRCP, MACR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/43/2743/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/43/2743/contributors\">",
"     Robert H Shmerling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/43/2743/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/43/2743/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/43/2743/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed connective tissue disease (MCTD) was originally defined as a connective tissue disorder characterized by the presence of high titers of a distinct autoantibody in combination with clinical features commonly seen in systemic lupus erythematosus (SLE), scleroderma, and polymyositis (referred to as overlap syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/1\">",
"     1",
"    </a>",
"    ]. The antigen recognized by these antibodies, originally called a ribonuclease-sensitive extractable nuclear antigen (RNAse sensitive ENA), is known to be a U1 ribonucleoprotein (RNP) complex. The presence of antibodies to U1 RNP remains a sine qua non for the diagnosis of this disorder; indeed, their emergence often precedes the onset of clinical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The immunobiology of anti-U1 RNP antibodies in mixed connective tissue disease will be reviewed here. The clinical manifestations, diagnosis, prognosis, and treatment of this disorder, as well as a general discussion of anti-RNP autoantibodies, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43401?source=see_link\">",
"     \"Clinical manifestations of mixed connective tissue disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3447?source=see_link\">",
"     \"Definition and diagnosis of mixed connective tissue disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19095?source=see_link\">",
"     \"Prognosis and treatment of mixed connective tissue disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=see_link&amp;anchor=H8#H8\">",
"     \"Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP\", section on 'Anti-Sm and anti-U1 RNP antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERATION OF U1 RNP AUTOIMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antibody response in patients with MCTD is very vigorous and is characterized by a hypergammaglobulinemia that can amount to 30 percent of the total serum immunoglobulins (Ig) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/4\">",
"     4",
"    </a>",
"    ]. In the laboratory, this antibody response is first evident as a very high titer speckled antinuclear antibody (ANA) pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/2\">",
"     2",
"    </a>",
"    ]. The titer is often greater than 1:1000 and is sometimes greater than 1:10,000; this finding should prompt the measurement of antibodies to U1 RNP, Sm, Ro, and La.",
"   </p>",
"   <p>",
"    The specificity of the antibodies most closely related to the clinical features of MCTD is for a 70 kD epitope on U1 RNP molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/5\">",
"     5",
"    </a>",
"    ]. This epitope has been further characterized as the RNA-binding domain on the peptide component of U1 RNP that spans residues 92 to 202 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/6\">",
"     6",
"    </a>",
"    ]. Anti-U1 RNP antibodies display Ig class switching from IgM to IgG, as evidenced by variable region mutations, a feature that is typical of a T-cell dependent B-cell maturation response [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The interaction of T-cell receptors and peptides presented by human leukocyte antigen (HLA) molecules is a critical event in the generation of autoimmunity. The 70 kD anti-U1 RNP antibody response is associated with",
"    <span class=\"nowrap\">",
"     CD4/Th1",
"    </span>",
"    T cells expressing a HLA-DR4 or -DR2 phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/8\">",
"     8",
"    </a>",
"    ]. DNA sequencing of HLA-DB genes has revealed that DR2 and DR4-positive patients share a common set of amino acids in the beta chain at positions 26, 28, 30, 31, 32, 70, and 73 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/9\">",
"     9",
"    </a>",
"    ]. Such amino acids form a pocket for antigen binding (",
"    <a class=\"graphic graphic_figure graphicRef72185 \" href=\"UTD.htm?12/28/12737\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is increasing evidence that the innate immune response is often a mechanism whereby antigens are &ldquo;focused&rdquo; as a prelude to the T-cell recognition that is characteristic of adaptive immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/10\">",
"     10",
"    </a>",
"    ]. Pathogen-associated pattern recognition receptors of innate immunity, so-called Toll-like receptors (TLRs), include molecules that recognize single-stranded DNA (TLR3) and double-stranded RNA (TLR7, TLR8). This may be of some relevance to U1 RNP autoimmunity, as 70 kD reactive T-cell clones preferentially recognize a residue within the RNA binding portion of the 70 kD peptide [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/11\">",
"     11",
"    </a>",
"    ], and U1 RNA can induce an innate immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INITIATION OF AN AUTOANTIBODY RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of an autoantibody-mediated disease is the result of a complex interaction between genetic and environmental factors. There is increasing information concerning the role of both of these factors in the pathogenesis of MCTD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/7\">",
"     7",
"    </a>",
"    ]. Autoimmunity is often antigen-driven by components of subcellular particles (eg, spliceosomes, nucleosomes, and proteasomes) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Autoimmunity to nucleosomal components",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nucleosomes are the compact building blocks of chromatin and consist of an octamer of two copies of histones H2A, H2B, H3, and H4, wrapped around approximately 146 base pairs of DNA. During apoptosis, endonucleases cleave chromatin with the liberation of nucleosomal particles. Following the release into the cytoplasm, nucleosomes migrate to the surface of the dying cell [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/14\">",
"     14",
"    </a>",
"    ] and, thus, become accessible to B-cell receptors. Nucleosomal antibodies are directed to antigenic determinants on the intact nucleosome rather than its individual components, DNA, and histones [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/13\">",
"     13",
"    </a>",
"    ]. In a study of 496 patients with 13 different connective tissue diseases and of 100 patients with hepatitis C, antinucleosome antibodies were found only in the sera of patients with systemic lupus erythematosus, systemic sclerosis, and MCTD (72, 46, and 45 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Autoimmunity to spliceosomal components",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmunity to specific components of the spliceosome is the immunological signature of MCTD. Spliceosomes are complex nuclear particles that are involved in the processing of pre-messenger RNA into mature &ldquo;spliced RNA.&rdquo; The 26S proteasome is a large subcellular particle involved in the degradation of proteins that have been tagged with ubiquitin and the generation peptides for presentation by the MHC class I molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/16\">",
"     16",
"    </a>",
"    ]. Certain components of the spliceosome are common targets of autoimmunity in the diffuse connective tissue diseases (DCTDs). Furthermore, it appears that post-translational modifications of these molecules, as occur during apoptosis, are often associated with increased immunogenicity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/17\">",
"     17",
"    </a>",
"    ]. There are two major spliceosomal sub-units that are antigenic targets in autoimmunity: 1) small nuclear ribonucleoprotein protein particles (snRNP); and 2) heterogeneous nuclear RNP particles (hnRNP).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Small nuclear RNP particles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The small nuclear RNP particles (snRNPs) contain small RNA species ranging in size from 80 to 350 nucleotides that are complexed with proteins. These RNAs contain a high content of uridine and are, therefore, called U-RNAs; five different U-RNAs were defined on the basis of immunoprecipitation (U1, U2, U4, U5, and U6). Autoantibodies to these complexes are mainly directed to the protein components.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anti-Sm antibodies precipitate five proteins with molecular weights of 28,000 (B&rsquo;B), 16,000 (D), 13,000 (E), 12,000 (F), and 11,000 (G); five of these polypeptides are common to the U1, U2, U4, U5, and U6 RNAs.",
"     </li>",
"     <li>",
"      Anti-RNP antibodies precipitate three proteins with molecular weights of 68,000 (70K), 33,000 (A&rsquo;), and 22,000 (C); these polypeptides are",
"      <strong>",
"       uniquely",
"      </strong>",
"      associated with U1 RNA. The clinical correlates considered to be distinctive of MCTD are associated with the presence of antibodies with 70 kD specificity, with an immunodominant epitope embracing amino acid residue 125 flanked by important conformational residues at positions 119 to 126 [",
"      <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/5\">",
"       5",
"      </a>",
"      ]. On the other hand, SLE is associated with anti-Sm antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Heterogeneous nuclear RNP particles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The heterogeneous nuclear RNP particles (hnRNP) contain pre-mRNA associated with about 30 small proteins that are all structurally related and that have molecular weights of 33 to 43 kD. Nine hnRNP core proteins have been designated A1, A2, B1a, B1b, B1c, B2, C1, C2, and C3.",
"   </p>",
"   <p>",
"    Anti-RA33 antibodies are those that target the 33 kD hnRNP-A2 protein; increased concentrations of these autoantibodies are found in about one-third of sera from patients with rheumatoid arthritis (RA), SLE, and MCTD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/19\">",
"     19",
"    </a>",
"    ]. The antigenic epitopes of hnRNP-A2 contain two RNA binding regions at the N-terminal end and at a glycine rich C-terminal region. Antibodies in RA and SLE sera preferentially react with the complete second RNA binding domain, whereas MCTD sera target an epitope that spans both RNA binding domains [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     IMMUNE RECOGNITION OF INTRACELLULAR PARTICLES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Epitope spreading",
"    </span>",
"    &nbsp;&mdash;&nbsp;A T cell only responds to a small antigenic peptide fragment presented by HLA molecules on antigen presenting cells (APC). T cells subsequently release cytokines that stimulate specific B cells to produce antibodies to the peptide fragment (",
"    <a class=\"graphic graphic_figure graphicRef76274 \" href=\"UTD.htm?43/38/44653\">",
"     figure 2",
"    </a>",
"    ). The antibody response to just one component of an intracellular structure, such as a spliceosome, will result in the uptake of the entire particle by antigen processing cells (APC), which include B cells. Thus, all the proteins making up the particle will be subject to antigen processing with peptide presentation linked to their affinity to class II HLA antigens. Depending upon the polymorphisms of the host&rsquo;s HLA molecules, there will be a spreading of the antibody response to include some of these other antigens. This process is called &ldquo;epitope spreading&rdquo; and is a critical step in the development of linked antibody responses [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For example, the induction of an immune response to one component of a U1 RNP complex can induce a diversified autoantibody response to other components of the complex (",
"    <a class=\"graphic graphic_figure graphicRef69246 \" href=\"UTD.htm?10/18/10543\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. In this way, an immune response becomes modified over time, and this change has been associated with changes in the clinical picture [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The mechanism whereby these &ldquo;hidden&rdquo; intracellular molecules become autoantigens is an area of ongoing research. The two main theories are apoptotic modification [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/27\">",
"     27",
"    </a>",
"    ] and molecular mimicry [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Apoptotic modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biochemical hallmark of apoptosis is the cleavage of DNA into oligonucleotides that produce characteristic &ldquo;DNA ladders&rdquo; when separated on agarose gels. Interestingly, similar DNA ladders are found in the serum of lupus patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/29\">",
"     29",
"    </a>",
"    ]. Although rheumatic disease autoantigens are not unified by common structure or function, they have the common feature of becoming clustered and concentrated in the surface blebs of apoptotic cells (",
"    <a class=\"graphic graphic_figure graphicRef71513 \" href=\"UTD.htm?17/58/18337\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/30\">",
"     30",
"    </a>",
"    ]. It is hypothesized that the cell surface translocation of snRNPs during apoptosis facilitates the exposure of modified antigens to the immune system [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Apoptosis generates modified proteins, through cleavage with a class of enzymes called caspases. During the process of apoptosis, several enzyme systems are upregulated with resulting post-translational modifications of the cleaved proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/32\">",
"     32",
"    </a>",
"    ]. It is thought that these modifications, which include citrullination, phosphorylation, dephosphorylation, transglutamination, and conjugation to ubiquitin, render the molecules more antigenic. As an example, the U1 70 kD protein is specifically cleaved by the enzyme caspase-3, converting it into a C-terminally truncated 40 kD fragment which is still associated with U1 RNA and which preferentially induces a 70 kD immune response in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/33\">",
"     33",
"    </a>",
"    ]. Antibodies to the apoptotically-cleaved U1 70 kD protein are more specific markers for MCTD than those directed against the intact protein [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Molecular mimicry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial stimulus for a first antibody response may be a nonself protein possessing a peptide region that mimics a self-epitope, so called molecular mimicry [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/35\">",
"     35",
"    </a>",
"    ]. The most likely environmental triggers are infectious agents that display self-like peptides. A critical limitation to molecular mimicry is the necessity for the antigenic sequence to undergo recognition via a T-cell receptor (TCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/36\">",
"     36",
"    </a>",
"    ]. Helper T lymphocytes (CD4+) usually recognize peptides of 12 to 16 amino acids in the context of HLA class II molecules.",
"   </p>",
"   <p>",
"    However, T-cell antigen recognition is highly degenerate, and smaller peptides may be recognized. In some instances, these fragments are more immunostimulatory than the parent ligand [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/37\">",
"     37",
"    </a>",
"    ]. This receptor degeneracy expands the potential for molecular mimicry, as the universe of molecules containing a pentapeptide is many times greater than for a 12 amino residue peptide. If a virus has a stretch of amino acids identical to such an immunostimulatory peptide, an autoimmune response may result [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/38\">",
"     38",
"    </a>",
"    ]. This has been suggested for the following peptide sequences:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A conserved pol sequence from human immunodeficiency virus type 1 (HIV-1) was found in 91 percent of DNA isolated from the serum of patients with MCTD [",
"      <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The murine retroviral P30 GAG antigen of the human influenza B virus has sequence homologous to the 68 kD peptide of U1 RNA [",
"      <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 33 percent homology exists between the 68 kD epitope (GRAFBTIG) and a B-3 loop of HIV-1 glycoprotein P120-41 [",
"      <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibodies against the P35 and P24 GAG proteins of HIV-1 are found in 75 percent of patients with MCTD, in 64 percent of patients with SLE, and in 63 percent of patients with discoid SLE but are not found in patients with subacute cutaneous LE [",
"      <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immunization of rabbits with a fragment of the Epstein Barr (EB) virus antigen EBNA-1 (the PPPGRRP region) resulted in an antibody response against the lupus-associated autoantigens Sm B&rsquo;, RNP-A, and RNP-C and in the development of leukopenia. It was suggested that the EB virus is a strong candidate for molecular mimicry in SLE-MCTD pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2743/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once an immune response to one component of an infectious agent has been elicited, other proteins or epitopes may become antigenic by the process of epitope spreading.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19769433\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The vigorous innate and adaptive immune response resulting in anti-U1 RNP antibodies in patients with MCTD may result in hypergammaglobulinemia; the antibodies in these patients typically produce a very high titer speckled antinuclear antibody pattern. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Generation of U1 RNP autoimmunity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anti-RNP antibodies precipitate three proteins with molecular weights of 68,000 (70K), 33,000 (A&rsquo;), and 22,000 (C); these polypeptides are uniquely associated with U1 RNA. The U1-RNA protein complex comprises one of the small nuclear RNP particles which are a subunit of the spliceosome. The clinical findings characteristic of MCTD are associated with the presence of antibodies with specificity for the 70 kD protein. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initiation of an autoantibody response'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Autoimmunity to spliceosomal components'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Small nuclear RNP particles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Heterogeneous nuclear RNP particles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with MCTD may also have antibodies to heterogeneous nuclear RNP particles, which are another subunit of the spliceosome, and to the nucleosome. The former type of autoantibody may also be seen in patients either with rheumatoid arthritis or with systemic lupus erythematosus (SLE), and the latter type may be seen in patients either with SLE or with systemic sclerosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Autoimmunity to nucleosomal components'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Heterogeneous nuclear RNP particles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Apoptotic modification and molecular mimicry have each been proposed as mechanisms by which intracellular molecules, such as components of U1 RNP, become autoantigens. Epitope spreading is a critical step in the linked and diversified anti-U1 RNP antibody response. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Epitope spreading'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Apoptotic modification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Molecular mimicry'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/1\">",
"      Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972; 52:148.",
"     </a>",
"    </li>",
"    <li>",
"     Bennett RM. Scleroderma, inflammatory myopathies, and overlap syndromes. In: Textbook of Rheumatology, 8th, Harris ED Jr (Ed), WB Saunders, Philadelphia 2008. p.1381.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/3\">",
"      Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/4\">",
"      Maddison PJ, Reichlin M. Quantitation of precipitating antibodies to certain soluble nuclear antigens in SLE. Arthritis Rheum 1977; 20:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/5\">",
"      Welin Henriksson E, Wahren-Herlenius M, Lundberg I, et al. Key residues revealed in a major conformational epitope of the U1-70K protein. Proc Natl Acad Sci U S A 1999; 96:14487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/6\">",
"      Degen WG, Pieffers M, Welin-Henriksson E, et al. Characterization of recombinant human autoantibody fragments directed toward the autoantigenic U1-70K protein. Eur J Immunol 2000; 30:3029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/7\">",
"      Hoffman RW, Maldonado ME. Immune pathogenesis of Mixed Connective Tissue Disease: a short analytical review. Clin Immunol 2008; 128:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/8\">",
"      Greidinger EL, Gazitt T, Jaimes KF, Hoffman RW. Human T cell clones specific for heterogeneous nuclear ribonucleoprotein A2 autoantigen from connective tissue disease patients assist in autoantibody production. Arthritis Rheum 2004; 50:2216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/9\">",
"      Kaneoka H, Hsu KC, Takeda Y, et al. Molecular genetic analysis of HLA-DR and HLA-DQ genes among anti-U1-70-kd autoantibody positive connective tissue disease patients. Arthritis Rheum 1992; 35:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/10\">",
"      Lanzavecchia A, Sallusto F. Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr Opin Immunol 2007; 19:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/11\">",
"      Greidinger EL, Zang YJ, Jaimes K, et al. CD4+ T cells target epitopes residing within the RNA-binding domain of the U1-70-kDa small nuclear ribonucleoprotein autoantigen and have restricted TCR diversity in an HLA-DR4-transgenic murine model of mixed connective tissue disease. J Immunol 2008; 180:8444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/12\">",
"      Hoffman RW, Gazitt T, Foecking MF, et al. U1 RNA induces innate immunity signaling. Arthritis Rheum 2004; 50:2891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/13\">",
"      Decker P. Nucleosome autoantibodies. Clin Chim Acta 2006; 366:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/14\">",
"      Radic M, Marion T, Monestier M. Nucleosomes are exposed at the cell surface in apoptosis. J Immunol 2004; 172:6692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/15\">",
"      Amoura Z, Koutouzov S, Chabre H, et al. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum 2000; 43:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/16\">",
"      Rivett AJ, Hearn AR. Proteasome function in antigen presentation: immunoproteasome complexes, Peptide production, and interactions with viral proteins. Curr Protein Pept Sci 2004; 5:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/17\">",
"      Utz PJ, Anderson P. Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens. Arthritis Rheum 1998; 41:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/18\">",
"      Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity 2005; 38:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/19\">",
"      Siapka S, Patrinou-Georgoula M, Vlachoyiannopoulos PG, Guialis A. Multiple specificities of autoantibodies against hnRNP A/B proteins in systemic rheumatic diseases and hnRNP L as an associated novel autoantigen. Autoimmunity 2007; 40:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/20\">",
"      Skriner K, Sommergruber WH, Tremmel V, et al. Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease. J Clin Invest 1997; 100:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/21\">",
"      Deshmukh US, Bagavant H, Lewis J, et al. Epitope spreading within lupus-associated ribonucleoprotein antigens. Clin Immunol 2005; 117:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/22\">",
"      Monneaux F, Muller S. Key sequences involved in the spreading of the systemic autoimmune response to spliceosomal proteins. Scand J Immunol 2001; 54:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/23\">",
"      Fatenejad S, Mamula MJ, Craft J. Role of intermolecular/intrastructural B- and T-cell determinants in the diversification of autoantibodies to ribonucleoprotein particles. Proc Natl Acad Sci U S A 1993; 90:12010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/24\">",
"      Steiner G, Shovman O, Skriner K, et al. Induction of anti-RA33 hnRNP autoantibodies and transient spread to U1-A snRNP complex of spliceosome by idiotypic manipulation with anti-RA33 antibody preparation in mice. Clin Exp Rheumatol 2002; 20:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/25\">",
"      Tuohy VK, Kinkel RP. Epitope spreading: a mechanism for progression of autoimmune disease. Arch Immunol Ther Exp (Warsz) 2000; 48:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/26\">",
"      Greidinger EL, Hoffman RW. The appearance of U1 RNP antibody specificities in sequential autoimmune human antisera follows a characteristic order that implicates the U1-70 kd and B'/B proteins as predominant U1 RNP immunogens. Arthritis Rheum 2001; 44:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/27\">",
"      Mahoney JA, Rosen A. Apoptosis and autoimmunity. Curr Opin Immunol 2005; 17:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/28\">",
"      Mihara S, Suzuki N, Takeba Y, et al. Combination of molecular mimicry and aberrant autoantigen expression is important for development of anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus. Clin Exp Immunol 2002; 129:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/29\">",
"      Rumore PM, Steinman CR. Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone. J Clin Invest 1990; 86:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/30\">",
"      Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/31\">",
"      Hof D, Raats JM, Pruijn GJ. Apoptotic modifications affect the autoreactivity of the U1 snRNP autoantigen. Autoimmun Rev 2005; 4:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/32\">",
"      Graham KL, Utz PJ. Sources of autoantigens in systemic lupus erythematosus. Curr Opin Rheumatol 2005; 17:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/33\">",
"      Greidinger EL, Foecking MF, Magee J, et al. A major B cell epitope present on the apoptotic but not the intact form of the U1-70-kDa ribonucleoprotein autoantigen. J Immunol 2004; 172:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/34\">",
"      Hof D, Cheung K, de Rooij DJ, et al. Autoantibodies specific for apoptotic U1-70K are superior serological markers for mixed connective tissue disease. Arthritis Res Ther 2005; 7:R302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/35\">",
"      Davies JM. Molecular mimicry: can epitope mimicry induce autoimmune disease? Immunol Cell Biol 1997; 75:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/36\">",
"      Wucherpfennig KW. Structural basis of molecular mimicry. J Autoimmun 2001; 16:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/37\">",
"      Hemmer B, Kondo T, Gran B, et al. Minimal peptide length requirements for CD4(+) T cell clones--implications for molecular mimicry and T cell survival. Int Immunol 2000; 12:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/38\">",
"      Oldstone MB. Molecular mimicry and immune-mediated diseases. FASEB J 1998; 12:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/39\">",
"      Prokop J, Jagodzinski PP. Identification of retroviral conserved pol sequences in serum of mixed connective tissue disease and systemic sclerosis patients. Biomed Pharmacother 2004; 58:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/40\">",
"      Maul GG, Jimenez SA, Riggs E, Ziemnicka-Kotula D. Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I: sequence similarity with retroviral p30gag protein suggests a possible cause for autoimmunity in systemic sclerosis. Proc Natl Acad Sci U S A 1989; 86:8492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/41\">",
"      Douvas A, Takehana Y. Cross-reactivity between autoimmune anti-U1 snRNP antibodies and neutralizing epitopes of HIV-1 gp120/41. AIDS Res Hum Retroviruses 1994; 10:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/42\">",
"      Ranki A, Kurki P, Riepponen S, Stephansson E. Antibodies to retroviral proteins in autoimmune connective tissue disease. Relation to clinical manifestations and ribonucleoprotein autoantibodies. Arthritis Rheum 1992; 35:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2743/abstract/43\">",
"      Poole BD, Gross T, Maier S, et al. Lupus-like autoantibody development in rabbits and mice after immunization with EBNA-1 fragments. J Autoimmun 2008; 31:362.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1815 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-17F8E0A872-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_43_2743=[""].join("\n");
var outline_f2_43_2743=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19769433\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERATION OF U1 RNP AUTOIMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INITIATION OF AN AUTOANTIBODY RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Autoimmunity to nucleosomal components",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Autoimmunity to spliceosomal components",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Small nuclear RNP particles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Heterogeneous nuclear RNP particles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      IMMUNE RECOGNITION OF INTRACELLULAR PARTICLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Epitope spreading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Apoptotic modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Molecular mimicry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19769433\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1815\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1815|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/28/12737\" title=\"figure 1\">",
"      Shared AAs in DR2 and DR4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/38/44653\" title=\"figure 2\">",
"      B and T cells and Ab production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/18/10543\" title=\"figure 3\">",
"      Epitope spreading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/58/18337\" title=\"figure 4\">",
"      Necrosis versus apoptosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=related_link\">",
"      Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43401?source=related_link\">",
"      Clinical manifestations of mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3447?source=related_link\">",
"      Definition and diagnosis of mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19095?source=related_link\">",
"      Prognosis and treatment of mixed connective tissue disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_43_2744="Treatment of Lambert-Eaton myasthenic syndrome";
var content_f2_43_2744=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of Lambert-Eaton myasthenic syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/43/2744/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/43/2744/contributors\">",
"     David H Weinberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/43/2744/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/43/2744/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/43/2744/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/43/2744/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/43/2744/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/43/2744/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lambert-Eaton myasthenic syndrome (LEMS) is an uncommon disorder of neuromuscular junction transmission with the primary clinical manifestation of muscle weakness. Knowledge of subtle clinical features and laboratory abnormalities that accompany LEMS permits the early identification of the disorder. Early recognition of LEMS is particularly important because of its strong association with small cell lung cancer (SCLC). Although LEMS can occur at any point in the course of SCLC, it may serve as a marker for early disease, and thus allow more effective treatment of this malignancy.",
"   </p>",
"   <p>",
"    This topic will review treatment for LEMS. The clinical features and diagnosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=see_link\">",
"     \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION FOR MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aggressive search for a primary underlying malignancy in patients with any risk factors for small cell lung is central to the management of patients with Lambert-Eaton myasthenic syndrome (LEMS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=see_link\">",
"     \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Small cell lung cancer (SCLC) is the most common associated tumor in patients with LEMS. Although available evidence suggests that early diagnosis does",
"    <strong>",
"     not",
"    </strong>",
"    confer longer survival in SCLC, there is some evidence that the presence of LEMS does imply a better prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of evaluating patients for occult SCLC was illustrated by a series of 100 patients with LEMS seen in a neurology clinic between 1998 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/3\">",
"     3",
"    </a>",
"    ]. With a minimum follow-up of three years, 54 patients had been diagnosed with SCLC. Overall, 92 percent of those with SCLC were diagnosed within three months and 96 percent within one year of their evaluation for LEMS. The most useful screening procedure was computed tomography (CT) of the thorax, which was more sensitive than routine chest x-ray (sensitivity 93 versus 51 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/3\">",
"     3",
"    </a>",
"    ]. Positron emission tomography (PET) was useful in selected cases and should be considered for any patient at the initial workup in whom the chest CT is nondiagnostic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17080?source=see_link\">",
"     \"Computed tomographic and positron emission tomographic scanning of pulmonary nodules\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2010 taskforce recommended repeat screening in three to six months after an initial negative malignancy evaluation, followed by screening every six months up until two years in patients with LEMS if testing remains unrevealing [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\", section on 'Occult malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of SOX (SRY-related HMG box) antibodies may distinguish paraneoplastic LEMS from nontumor LEMS cases. In one report, the presence of SOX antibodies discriminated LEMS with SCLC from nontumor LEMS cases with a sensitivity and specificity of 67 and 95 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/5\">",
"     5",
"    </a>",
"    ]. The presence of these antibodies did not confer any survival benefit. Thus, unlike a variety of other autoantibodies associated with SCLC, SOX antibodies are tumor markers and should not be present in nontumor cases. Although not yet commercially available, the technique is being refined and should be available soon. In another study from the same group, clinical factors within the first three months from LEMS onset that independently predicted the presence of small cell lung cancer were age &ge;50 years, history of smoking at diagnosis, weight loss &ge;5 percent, bulbar involvement, erectile dysfunction in men, and Karnofsky performance status (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"     table 1",
"    </a>",
"    ) score &lt;70 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/6\">",
"     6",
"    </a>",
"    ]. When all these factors were present, the likelihood of small cell lung cancer was 100 percent. When all were absent, the likelihood was zero.",
"   </p>",
"   <p>",
"    With treatment of SCLC, many patients with LEMS experience remission in both the clinical symptoms of muscle weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/7-9\">",
"     7-9",
"    </a>",
"    ] and the electrophysiologic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/10\">",
"     10",
"    </a>",
"    ]. However, weakness occasionally persists even with treatment of SCLC. Proximal weakness is common in patients with small cell lung cancer even in the absence of LEMS or other specific neurologic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of SCLC is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4183?source=see_link\">",
"     \"Treatment of refractory and relapsed small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=see_link\">",
"     \"Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SYMPTOMATIC THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several medications increase the amount of acetylcholine available at the postsynaptic membrane. The most effective agents increase the presynaptic release of acetylcholine and thereby reverse the underlying physiologic deficit present in LEMS. If adequate to induce stable functional muscle strength, no further treatment may be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Guanidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/5/31826?source=see_link\">",
"     Guanidine",
"    </a>",
"    inhibits voltage-gated potassium channels and enhances the release of acetylcholine [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/12\">",
"     12",
"    </a>",
"    ]. It was the first beneficial agent for the symptomatic treatment of LEMS. However, significant toxicity has limited its use [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. The wide range of complications includes bone marrow suppression and renal toxicity.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/5/31826?source=see_link\">",
"     Guanidine",
"    </a>",
"    doses up to 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day were advocated in early studies, but such doses are associated with considerable risk [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/16\">",
"     16",
"    </a>",
"    ]. A lower dose regimen (maximum 1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    has been proposed and is reported to be less toxic [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Acetylcholinesterase inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Routine hematologic, hepatic, and renal monitoring are necessary with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/5/31826?source=see_link\">",
"     guanidine",
"    </a>",
"    , especially at total doses higher than 1000",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Aminopyridines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aminopyridines are beneficial in patients with LEMS. The mechanism of action is a significant prolongation of the nerve terminal membrane depolarization, which enhances calcium entry and thereby improves the release of acetylcholine.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/36/6725?source=see_link\">",
"     Dalfampridine",
"    </a>",
"    (fampridine, 4-aminopyridine) was the first effective agent of this class. However, its use is limited by frequent toxic side effects, particularly seizures, which occur in the therapeutic range due to its easy entry into the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    3,4-Diaminopyridine (3,4-DAP) is the best-tolerated aminopyridine due to its limited central nervous system (CNS) penetration. The effectiveness of 3,4-DAP compared with placebo for improving motor and autonomic symptoms in LEMS was demonstrated in four small randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. In these studies, 3,4-DAP improved both muscle strength and resting compound muscle action potential amplitude [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/36/6725?source=see_link\">",
"     dalfampridine",
"    </a>",
"    , the side effects of 3,4-DAP at typical therapeutic doses are usually mild, mainly perioral and extremity paresthesias. However, seizures have occurred at higher doses [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    3,4-DAP should be used cautiously at the lowest dose possible in patients with epilepsy. A maximum total 3,4-DAP dose of 80",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    typically given as 20 mg four times daily, is recommended by some experts to minimize the risk of seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/19\">",
"     19",
"    </a>",
"    ]. However, 3,4-DAP doses up to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    have been widely used.",
"   </p>",
"   <p>",
"    3,4-DAP is available in Europe but is not approved for routine use in the United States. However, 3,4-DAP is available from a number of compounding pharmacies in the United States. In addition, 3,4-DAP can be obtained on a compassionate use basis for patients with LEMS from Jacobus Pharmaceutical in Princeton, New Jersey, USA (phone 609-921-7447 and fax 609-799-1176).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Acetylcholinesterase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acetylcholinesterase inhibitors (AChEI) agents reduce the metabolism of acetylcholine, thereby increasing the amount available for acetylcholine receptor binding.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     Pyridostigmine",
"    </a>",
"    is the best-tolerated.",
"   </p>",
"   <p>",
"    The AChEIs are marginally effective in isolation for the treatment of LEMS. They have been used as adjunct treatment in patients receiving 3,4-diaminopyridine (3,4-DAP) in the hope that this combination, which is well tolerated, confers additional symptomatic benefit. However, the utility of this approach is uncertain and high-quality data are sparse. One randomized controlled crossover trial of nine patients with LEMS compared 3,4-DAP,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    , the combination of both drugs, and placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/22\">",
"     22",
"    </a>",
"    ]. There was no benefit for pyridostigmine, either alone or in combination with 3,4-DAP, for the outcomes of muscle strength and compound muscle action potential amplitude.",
"   </p>",
"   <p>",
"    The AChEIs can also be used with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/5/31826?source=see_link\">",
"     guanidine",
"    </a>",
"    . In a small observational study, the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    with low-dose guanidine was effective and considerably safer than higher-dose guanidine alone [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Guanidine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     Pyridostigmine",
"    </a>",
"    is used in a wide dose range between 30 and 180 mg at dosing intervals between three and six hours, depending upon side effects and clinical response. Nausea, abdominal cramping, and diarrhea are the major limiting factors, but there are no major systemic toxicities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     IMMUNOLOGIC THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of LEMS is synonymous with the presence of antibodies directed against voltage-gated calcium channels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with significant weakness and a limited response to the symptomatic therapies outlined above, a reduction in this aberrant immune response is often central to successful treatment. Several different strategies have been employed, including a variety of oral agents and immunomodifying treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immune globulin (IVIG) therapy, a nonspecific immunomodulating therapy, has proven useful in a number of antibody-mediated diseases such as MG. A number of small studies conducted in the mid-1990s suggested benefit in LEMS as well, with both clinical improvement and a reduction in the voltage-gated calcium channel antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/23-29\">",
"     23-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The only randomized trial of this therapy for LEMS involved nine patients who were treated in a crossover design with IVIG (1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day for two days) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/24\">",
"     24",
"    </a>",
"    ]. There was a statistically significant improvement in serial measurements of limb, respiratory, and bulbar muscle strength associated with IVIG treatment, and a nonsignificant improvement in the resting compound muscle action potential amplitude.",
"   </p>",
"   <p>",
"    The benefits of IVIG treatment seem to peak at approximately two to four weeks following the infusion (the half-life is roughly one month), followed by recurrent weakness over the subsequent weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. The use of maintenance IVIG for recurrent weakness has been both feasible and beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/25\">",
"     25",
"    </a>",
"    ]. Therefore, we suggest maintenance therapy with repeat IVIG infusions at 4 to 12 week intervals for patients with symptom recurrence who responded to initial IVIG treatment.",
"   </p>",
"   <p>",
"    Overall, IVIG is well tolerated, but particular problems as well as several idiosyncratic reactions can be induced by the large volume of fluid required and by the increase in serum viscosity that occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Numerous IVIG products are available with different relative toxicities based upon the formulation. Thus, a good working familiarity with these preparations is recommended, particularly when ordering treatment for patients who may be at higher risk of complications from IVIG. This category likely includes patients with renal insufficiency and a serum creatinine &gt;1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (&gt;133",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    cerebrovascular disease, peripheral artery disease, cardiovascular disease, or advanced age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Immunosuppressive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with significant weakness who do not experience marked improvement with symptomatic therapies, oral immunosuppressive agents are often the most practical and cost-effective treatment option. There are no large-scale treatment trials to guide medication selection, but many smaller studies and case reports have commented upon the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    alone [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/31\">",
"     31",
"    </a>",
"    ] or combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or plasmapheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/32-35\">",
"     32-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is typically started at a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day or 1 to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every other day [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/31\">",
"     31",
"    </a>",
"    ]. This dose is maintained until clinically significant improvement is evident, which may take several months. At that point, a slow tapering of the prednisone dose can begin. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Glucocorticoid tapering'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    can be added as a glucocorticoid sparing medication, typically starting at 50 mg twice a day, and increasing by 50 mg weekly up to a total dose of 2 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. Azathioprine is often given in divided doses to reduce gastrointestinal side effects, but it can be given as a single daily dose.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    may be substituted in patients who do not tolerate azathioprine [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/35\">",
"     35",
"    </a>",
"    ]. The standard adult dose is 1000 mg twice a day on an empty stomach, but doses up to 1500 mg twice a day are occasionally used.",
"   </p>",
"   <p>",
"    Although efficacy has not been well documented,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or the combination of IVIG and an oral immunosuppressive agent would be reasonable in patients with LEMS that is refractory to the more established agents [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective report, treatment with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    was associated with improvement but not remission in two patients with LEMS who had previously been treated with multiple other immunosuppressive therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Glucocorticoid tapering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid tapering should be individualized in patients with LEMS, based upon the clinical situation. A reasonable tapering regimen with either a daily or alternate-day glucocorticoid treatment program is to decrease the dose every two weeks by 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    until the dose is &le;20",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    or &le;30 mg every other day, at which point the dose reduction is slowed to 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    every two weeks. With doses &le;7.5",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    tapering is often further slowed to 2 to 2.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    every two weeks.",
"   </p>",
"   <p>",
"    Attention to symptoms suggestive of adrenal insufficiency is important for patients who have been exposed to daily glucocorticoids for longer than three weeks, particularly those taking the dose equivalent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    &ge;10",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    However, adrenal testing is seldom needed.",
"   </p>",
"   <p>",
"    The risk of hypothalamic-pituitary-adrenal axis suppression and adrenal insufficiency due to glucocorticoid therapy and tapering is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=see_link&amp;anchor=H18#H18\">",
"     \"Pharmacologic use of glucocorticoids\", section on 'HPA axis suppression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98835328\">",
"    <span class=\"h2\">",
"     Plasma exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma exchange (plasmapheresis) is an attractive therapy for a putative antibody mediated disorder, and benefit was noted in the early 1980s in several small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/32-34,37\">",
"     32-34,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, patients with LEMS do not respond as rapidly to plasma exchange as do those with myasthenia gravis (MG). In addition, the benefit of plasma exchange is only short term, due to continued production of the offending antibodies, and repeated treatment is necessary. Nevertheless, combined therapy with plasma exchange and oral immunosuppressive agents remains a beneficial approach for some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/33,37\">",
"     33,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are inadequate data to determine the best plasma exchange treatment protocol for LEMS. Five exchanges (3 to 5 L of plasma each) over 7 to 14 days is the typical course of treatment for MG, and this represents a reasonable protocol for patients with LEMS, given the pathogenic similarities between the two disorders. On the other hand, anecdotal evidence suggests that more than five exchanges may be necessary to achieve maximum improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of plasma exchange is limited for many patients by several factors, including the need for vascular access, the limited availability of the procedure in many geographic areas, and the high cost of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT STRATEGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification and aggressive treatment of an inducing malignancy is the first priority for paraneoplastic LEMS (",
"    <a class=\"graphic graphic_algorithm graphicRef54686 \" href=\"UTD.htm?3/37/3679\">",
"     algorithm 1",
"    </a>",
"    ). Treatment of the underlying malignancy may be the only intervention necessary to produce improvement in neurologic symptoms. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Evaluation for malignancy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Beyond malignancy treatment, most experts recommend similar symptomatic and immunologic treatments for patients with autoimmune LEMS and paraneoplastic LEMS (",
"    <a class=\"graphic graphic_algorithm graphicRef54686 \" href=\"UTD.htm?3/37/3679\">",
"     algorithm 1",
"    </a>",
"    ). The goals of treatment are an improvement in muscle weakness rather than reduction in antibody levels or improvement in electrophysiologic measures.",
"   </p>",
"   <p>",
"    For mild symptomatic disease, a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    in doses between 30 to 120 mg every three to six hours is suggested. If the response is inadequate, 3,4-DAP, if available, can be added (at 10 to 25 mg three or four times daily). If 3,4-DAP is not available, low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/5/31826?source=see_link\">",
"     guanidine",
"    </a>",
"    can be added to pyridostigmine. Guanidine can be started at 5 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, given in three to four divided doses. While guanidine is safer at doses &le;1000",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    the dose can be gradually increased if necessary to a maximum of 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day with careful medical monitoring. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Guanidine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    More significant or refractory weakness will probably require a reduction in the disease-inducing voltage-gated calcium channel antibodies. A course of intravenous immune globulin (IVIG) (total dose of 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    over two to five days) is often effective, and maintenance therapy with repeat infusions at 4 to 12 week intervals (based upon symptoms) is a reasonable strategy. We suggest maintenance therapy with repeat IVIG infusions for patients with symptom recurrence who responded to initial IVIG treatment.",
"   </p>",
"   <p>",
"    Oral immunosuppressive agents are probably equally effective.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    has the widest experience but also the greatest breadth of side effects.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    or immunosuppressive agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    are less toxic than prednisone, but may not be as effective. However, some experts are reluctant to use oral immunosuppressive agents such as azathioprine in patients with cancer because of concerns that such treatment may exacerbate the malignancy.",
"   </p>",
"   <p>",
"    A common strategy, similar to that used to induce remission in myasthenia gravis (MG), is to start",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, or 1 to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every other day) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (2 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) simultaneously, followed later by an attempt to taper or discontinue prednisone. Unfortunately, this strategy is not as successful in patients with LEMS as it is in patients with MG [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2744/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other reasonable choices would be oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    alone, starting with the same daily or alternate day dosing,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    alone at 2 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, other oral immunosuppressives (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    ), or plasma exchange given as five or more exchanges (3 to 5 L of plasma each) over 7 to 14 days.",
"   </p>",
"   <p>",
"    Plasma exchange is more cumbersome than IVIG and is suggested for special circumstances such as IVIG intolerance or refractory disease in patients with a severe clinical course.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    can also be used for patients with disease that is refractory to the other agents listed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The aggressive search for and treatment of a primary underlying malignancy in patients with any risk factors for small cell lung is central to the management (",
"      <a class=\"graphic graphic_algorithm graphicRef54686 \" href=\"UTD.htm?3/37/3679\">",
"       algorithm 1",
"      </a>",
"      ) of patients with Lambert-Eaton myasthenic syndrome (LEMS). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evaluation for malignancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic therapies for LEMS include medications that increase the amount of acetylcholine available at the postsynaptic membrane. These are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/5/31826?source=see_link\">",
"       guanidine",
"      </a>",
"      , aminopyridines such as 3,4-diaminopyridine (3,4-DAP), and acetylcholinesterase inhibitors such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"       pyridostigmine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Symptomatic therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunologic therapies for LEMS include intravenous immune globulin (IVIG), oral immunosuppressive agents, and, least commonly, plasma exchange or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      . These treatments are thought to dampen the aberrant immune response that causes LEMS by reducing the antibodies directed at voltage-gated calcium channels in the presynaptic terminal of the neuromuscular junction. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Immunologic therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with LEMS with or without a malignancy who have mild persistent weakness, we suggest initial therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"       pyridostigmine",
"      </a>",
"      30 to 120 mg every three to six hours (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If this treatment is not beneficial, we suggest adding 3,4-DAP, 10 to 25 mg three to four times daily (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) if it is available. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment strategy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Acetylcholinesterase inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Aminopyridines'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      If 3,4-DAP is not available, an alternative is to add low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/5/31826?source=see_link\">",
"       guanidine",
"      </a>",
"      , starting at 5 to 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in three to four divided doses, gradually increasing as necessary. Guanidine dosing and toxicity are discussed above. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment strategy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Guanidine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with LEMS without malignancy or with a treated malignancy who have disabling weakness that is refractory to symptomatic therapies, we recommend treatment with immunomodulating therapy rather than no treatment (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We suggest initial use of IVIG or oral immunosuppressive agents rather than plasma exchange (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A typical course of IVIG is 2",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      total given over two to five days. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment strategy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Intravenous immune globulin'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Our preferred alternative regimen to IVIG is to simultaneously start oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day or 1 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every other day, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      2 to 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, followed later by an attempt to taper or discontinue prednisone. Other alternatives are discussed above. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment strategy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Dosing and tapering of prednisone is discussed in greater detail above. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Immunosuppressive agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Glucocorticoid tapering'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IVIG treatment typically produces only temporary improvement in weakness lasting four to eight weeks in patients with LEMS, after which relapsing weakness is likely to occur. For patients with symptom recurrence who respond to initial IVIG treatment, we suggest maintenance therapy with repeat IVIG infusions at 4 to 12 week intervals (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Intravenous immune globulin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment strategy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/1\">",
"      Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999; 353:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/2\">",
"      Wirtz PW, Lang B, Graus F, et al. P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J Neuroimmunol 2005; 164:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/3\">",
"      Titulaer MJ, Wirtz PW, Willems LN, et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 2008; 26:4276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/4\">",
"      Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011; 18:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/5\">",
"      Titulaer MJ, Klooster R, Potman M, et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol 2009; 27:4260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/6\">",
"      Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol 2011; 29:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/7\">",
"      Berglund S, Eriksson M, von Eyben FE, et al. Remission by chemotherapy of the Eaton-Lambert myasthenic syndrome in a patient with small cell bronchogenic carcinoma. Acta Med Scand 1982; 212:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/8\">",
"      Jenkyn LR, Brooks PL, Forcier RJ, et al. Remission of the Lambert-Eaton syndrome and small cell anaplastic carcinoma of the lung induced by chemotherapy and radiotherapy. Cancer 1980; 46:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/9\">",
"      Chalk CH, Murray NM, Newsom-Davis J, et al. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990; 40:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/10\">",
"      Oh SJ. SFEMG improvement with remission in the cancer-associated Lambert-Eaton myasthenic syndrome. Muscle Nerve 1989; 12:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/11\">",
"      Elrington GM, Murray NM, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991; 54:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/12\">",
"      Kalia J, Swartz KJ. Elucidating the molecular basis of action of a classic drug: guanidine compounds as inhibitors of voltage-gated potassium channels. Mol Pharmacol 2011; 80:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/13\">",
"      Blumhardt LD, Joekes AM, Marshall J, Philalithis PE. Guanidine treatment and impaired renal function in the Eaton-Lambert syndrome. Br Med J 1977; 1:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/14\">",
"      Kamenskaya MA, Elmqvist D, Thesleff S. Guanidine and neuromuscular transmission. I. Effect on transmitter release occurring spontaneously and in response to single nerve stimuli. Arch Neurol 1975; 32:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/15\">",
"      O SJ, Kim KW. Guanidine hydrochloride in the Eaton-Lambert syndrome. Electrophysiologic improvement. Neurology 1973; 23:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/16\">",
"      Sanders DB. Lambert-eaton myasthenic syndrome: diagnosis and treatment. Ann N Y Acad Sci 2003; 998:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/17\">",
"      Oh SJ, Kim DS, Head TC, Claussen GC. Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome. Muscle Nerve 1997; 20:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/18\">",
"      Murray NM, Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981; 31:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/19\">",
"      Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000; 54:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/20\">",
"      McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989; 321:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/21\">",
"      Oh SJ, Claussen GG, Hatanaka Y, Morgan MB. 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve 2009; 40:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/22\">",
"      Wirtz PW, Verschuuren JJ, van Dijk JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther 2009; 86:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/23\">",
"      Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2011; :CD003279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/24\">",
"      Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996; 47:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/25\">",
"      Muchnik S, Losavio AS, Vidal A, et al. Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin. Muscle Nerve 1997; 20:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/26\">",
"      Rich MM, Teener JW, Bird SJ. Treatment of Lambert-Eaton syndrome with intravenous immunoglobulin. Muscle Nerve 1997; 20:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/27\">",
"      Takano H, Tanaka M, Koike R, et al. Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody. Muscle Nerve 1994; 17:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/28\">",
"      Bird SJ. Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy. Neurology 1992; 42:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/29\">",
"      Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012; 78:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/30\">",
"      Wittstock M, Benecke R, Zettl UK. Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol 2003; 50:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/31\">",
"      Streib EW, Rothner AD. Eaton-Lambert myasthenic syndrome: long-term treatment of three patients with prednisone. Ann Neurol 1981; 10:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/32\">",
"      Lang B, Newsom-Davis J, Wray D, et al. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 1981; 2:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/33\">",
"      Dau PC, Denys EH. Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome. Ann Neurol 1982; 11:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/34\">",
"      Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984; 34:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/35\">",
"      Newsom-Davis J. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome. Semin Neurol 2003; 23:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/36\">",
"      Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011; 82:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/37\">",
"      Motomura M, Hamasaki S, Nakane S, et al. Apheresis treatment in Lambert-Eaton myasthenic syndrome. Ther Apher 2000; 4:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2744/abstract/38\">",
"      Maddison P, Lang B, Mills K, Newsom-Davis J. Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry 2001; 70:212.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5134 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-0C172D990F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_43_2744=[""].join("\n");
var outline_f2_43_2744=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION FOR MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SYMPTOMATIC THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Guanidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Aminopyridines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Acetylcholinesterase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      IMMUNOLOGIC THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Immunosuppressive agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Glucocorticoid tapering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98835328\">",
"      Plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT STRATEGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5134\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5134|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?3/37/3679\" title=\"algorithm 1\">",
"      Treatment strategy for Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5134|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 1\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=related_link\">",
"      Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=related_link\">",
"      Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17080?source=related_link\">",
"      Computed tomographic and positron emission tomographic scanning of pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=related_link\">",
"      Pathobiology and staging of small cell carcinoma of the lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23208?source=related_link\">",
"      Pharmacologic use of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4183?source=related_link\">",
"      Treatment of refractory and relapsed small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_43_2745="Palmar hand anatomy";
var content_f2_43_2745=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52608%7EPC%2F82236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52608%7EPC%2F82236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palmar hand anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 409px; height: 440px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The path of palmar arteries (red) and nerves (green) to the fingers is shown. Each digit is innervated by four digital nerves; the dorsal arteries and nerves are not shown in this figure. In order to achieve a complete anesthetic effect, it is necessary to block all four nerves.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plantar foot anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 507px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The path of plantar arteries (red) and nerves (green) to the toes is shown. Each digit is innervated by four digital nerves; the dorsal arteries and nerves are not shown in this figure. In order to achieve a complete anesthetic effect, it is necessary to block all four nerves. For a complete block of the great toe, there are additional branches that come up the dorsal aspect of the great toe that can be missed if anesthetic is only injected laterally and medially.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_43_2745=[""].join("\n");
var outline_f2_43_2745=null;
var title_f2_43_2746="Risk stratification after unstable angina or non-ST elevation myocardial infarction";
var content_f2_43_2746=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/43/2746/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/43/2746/contributors\">",
"     Jeffrey A Breall, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/43/2746/contributors\">",
"     Michael Simons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/43/2746/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/43/2746/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/43/2746/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/43/2746/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/43/2746/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among non-ST elevation acute coronary syndromes (ACS), unstable angina (UA) and non-ST elevation myocardial infarction (NSTEMI) differ primarily in whether the ischemia is severe enough to cause sufficient myocardial damage to release detectable quantities of a marker of myocardial injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link&amp;anchor=H2#H2\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with presumed unstable ischemic pain or ECG changes without ST elevation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NSTEMI is considered to be present if there is a typical rise and gradual fall (troponins) or more rapid rise and fall (CK-MB) of biochemical markers of myocardial necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      UA is considered to be present if there is no elevation in serum troponins or CK-MB, with or without electrocardiographic (ECG) changes indicative of ischemia (eg, ST segment depression or transient elevation or new T wave inversion).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since an elevation in serum troponins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CK-MB may not be detectable for hours after presentation, UA and NSTEMI are frequently indistinguishable at initial evaluation and will therefore be considered together here.",
"   </p>",
"   <p>",
"    Risk stratification of patients with an ACS begins upon presentation and is then a continuous process to predict those who are at high risk for further ischemic events or adverse outcomes. Among patients with",
"    <span class=\"nowrap\">",
"     UA/NSTEMI,",
"    </span>",
"    risk stratification begins with initial assessment to detect patients at immediate high risk. Subsequent evaluation is aimed at identifying patients who will benefit from an early invasive strategy at 4 to 48 hours and, finally, at predicting which patients are at increased risk after discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The general approach to risk stratification for patients with",
"    <span class=\"nowrap\">",
"     UA/NSTEMI",
"    </span>",
"    will be reviewed here, beginning with a short summary of the prognosis of patients with an ACS. The individual risk factors that influence prognosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=see_link\">",
"     \"Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk stratification for patients with an acute ST elevation MI (STEMI), who have usually been reperfused with primary percutaneous coronary intervention (PCI) or fibrinolytic therapy, and for those at risk for life-threatening arrhythmias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=see_link\">",
"     \"Risk stratification for cardiac events after acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of patients with an NSTEMI and UA compared to each other and to STEMI has been evaluated in a number of studies. The outcome is best with UA, while patients with an NSTEMI may have a lower in-hospital mortality but, in most studies, a similar or even worse long-term outcome than those with STEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. However, the applicability of the following observations to current clinical practice is uncertain since the prognosis of STEMI has improved with the increasing use of primary PCI rather than thrombolysis and the prognosis of NSTEMI and UA have improved with the increasing use of revascularization, stenting, and more aggressive antiplatelet therapy.",
"   </p>",
"   <p>",
"    The largest experience comes from the GUSTO IIb trial performed in the early 1990s of 12,142 patients in which patients with an ACS were diagnosed with STEMI, NSTEMI (using only CK-MB not troponins for diagnosis), and UA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/3\">",
"     3",
"    </a>",
"    ]. Among the patients with STEMI, primary PCI was performed in only 11 percent; among the patients with NSTEMI or UA, angiography and revascularization were performed in only 57 and 34 percent, respectively.",
"   </p>",
"   <p>",
"    The following findings in the three groups were noted, with the values significantly lower for UA at all time points:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mortality at 30 days was 6.1 (STEMI), 5.7 (NSTEMI), and 2.4 percent (UA)",
"     </li>",
"     <li>",
"      Mortality at six months was 8.0, 8.8, and 5.0 percent",
"     </li>",
"     <li>",
"      Mortality at one year was 9.6, 11.1, and 7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mortality rate in GUSTO IIb at one year was significantly higher with NSTEMI than STEMI (11.1 versus 9.6 percent). A similar finding was noted in the community-based observational study cited above of almost 6000 first MIs over a 23-year period; patients with a NSTEMI had a higher two year mortality than those with an STEMI (20 versus 11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The similar or worse prognosis in NSTEMI is in part related to more than a 50 percent prevalence of multivessel disease in affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/7\">",
"     7",
"    </a>",
"    ] and to a greater likelihood of residual ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. Thus, a significant amount of myocardium may remain at risk. In GUSTO-IIb, recurrent ischemia was more common with non-ST elevation ACS than with STEMI (35 versus 23 percent) and, in all groups, was associated with a two- to three-fold increase in mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/3\">",
"     3",
"    </a>",
"    ]. In patients with NSTEMI, for example, the one year survival for those with refractory, nonrefractory, and no recurrent ischemia was 23, 12, and 9 percent, respectively.",
"   </p>",
"   <p>",
"    Higher in-hospital and 30-day mortality rates after MI have been described in patients not enrolled in clinical trials. For STEMI and NSTEMI, the in-hospital mortality was 14 and 12 percent in the community-based observational study [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/4\">",
"     4",
"    </a>",
"    ] and the 30-day mortality was 11 and 7.4 percent in the Euro Heart Survey review of over 10,000 patients with an ACS in 103 hospitals (mostly academic) from 25 countries in Europe seen from late 2000 through May 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/6\">",
"     6",
"    </a>",
"    ]. In the latter report, 30-day mortality was again much lower for UA (1.7 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IMMEDIATE HIGH-RISK PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with any of the following features are deemed to be at such high risk that coronary angiography should proceed without delay [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiogenic shock",
"     </li>",
"     <li>",
"      Overt heart failure (HF) or severe left ventricular dysfunction",
"     </li>",
"     <li>",
"      Recurrent or persistent rest angina despite intensive medical therapy",
"     </li>",
"     <li>",
"      Hemodynamic instability due to mechanical complications (eg, acute mitral regurgitation, ventricular septal defect)",
"     </li>",
"     <li>",
"      Unstable ventricular arrhythmias",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The only reasons to exclude angiography in patients with any of the above risks would be if they would not consider revascularization or if they have underlying conditions that preclude PCI or coronary artery bypass grafting (CABG).",
"   </p>",
"   <p>",
"    Less severe degrees of HF, angina, and ventricular arrhythmias are also indications of increased risk (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=see_link&amp;anchor=H5#H5\">",
"     \"Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction\", section on 'Heart failure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=see_link&amp;anchor=H7#H7\">",
"     \"Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction\", section on 'Arrhythmias'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=see_link\">",
"     \"Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EARLY INVASIVE VERSUS CONSERVATIVE STRATEGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with",
"    <span class=\"nowrap\">",
"     UA/NSTEMI",
"    </span>",
"    who lack features indicating the need for immediate intervention, the next step in the risk stratification process is to identify patients who should be treated with an early invasive strategy. The factors that are considered in making this decision are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, an early invasive strategy consists of prompt catheterization and subsequent revascularization, if appropriate, once the patient has stabilized on initial medical therapy; angiography is usually performed within",
"    <strong>",
"     4 to 48 hours",
"    </strong>",
"    of admission. Randomized trials, such as TIMI IIIB, FRISC II, and TACTICS-TIMI 18 have shown that early intervention improves outcome in patients with any of the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Elevated cardiac enzymes, which identifies patients with NSTEMI",
"     </li>",
"     <li>",
"      ST depression on the electrocardiogram (ECG)",
"     </li>",
"     <li>",
"      Age greater than 65",
"     </li>",
"     <li>",
"      Accelerated angina within two months of admission",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Small elevations in cardiac enzymes in ACS are thought to reflect small, localized areas of infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/9\">",
"     9",
"    </a>",
"    ]. However, the adverse prognosis associated with this finding in NSTEMI may also be related to worse underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=see_link&amp;anchor=H16#H16\">",
"     \"Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction\", section on 'Serum troponins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association guidelines on non-ST elevation acute coronary syndromes recommended an early invasive strategy to ST segment depression, elevated cardiac enzymes (which identifies an NSTEMI), and a number of other factors in patients with an ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/11\">",
"     11",
"    </a>",
"    ]. The minority of patients deemed to be at low risk (TIMI risk score 0 to 2) (",
"    <a class=\"graphic graphic_figure graphicRef67473 \" href=\"UTD.htm?30/55/31614\">",
"     figure 1",
"    </a>",
"    ) can be treated with either an early invasive or conservative approach (see",
"    <a class=\"local\" href=\"#H7\">",
"     'TIMI risk score'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/2,12,13\">",
"     2,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our hospitals, most of these patients, particularly those with ST segment depression or elevated cardiac biomarkers, undergo early angiography in the absence of a contraindication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two other settings in which an early invasive approach is warranted because of a high risk for subsequent ischemic events: new angina following an acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/3,11\">",
"     3,11",
"    </a>",
"    ], and angina after PCI (now mostly involving stenting) or CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/11,14\">",
"     11,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link\">",
"     \"Periprocedural complications of percutaneous coronary intervention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=see_link\">",
"     \"Intracoronary stent restenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=see_link\">",
"     \"Long-term outcome after coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Absence of significant coronary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In different clinical trials, as well as in the CRUSADE registry, 9 to 14 percent of patients with a non-ST elevation ACS who undergo early angiography have no significant coronary stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/12,15-18\">",
"     12,15-18",
"    </a>",
"    ]. Approximately one-half of these patients have no coronary stenosis and one-half have a noncritical (less than 50 to 60 percent) coronary stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=see_link&amp;anchor=H10#H10\">",
"     \"Classification of unstable angina and non-ST elevation myocardial infarction\", section on 'Absence of significant coronary disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Such patients have a much better short-term prognosis than those with a critical culprit lesion. In a report from the PURSUIT trial, for example, the patients with no or mild coronary disease had a much lower rate of death or nonfatal MI at 30 days than those with significant disease (2 and 6 versus 17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/16\">",
"     16",
"    </a>",
"    ]. Similar findings were noted in a report from the CRUSADE registry [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/18\">",
"     18",
"    </a>",
"    ]. Among patients with an NSTEMI, the in-hospital death rate was significantly lower in the patients without significant coronary disease (0.65 versus 2.36 percent for those with coronary disease).",
"   </p>",
"   <p>",
"    Outcomes at one year in patients with normal or mild disease were provided in an analysis of 7656 patients pooled from three TIMI trials, which looked at a composite primary end point of death, MI, unstable angina requiring hospitalization, revascularization, or stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/15\">",
"     15",
"    </a>",
"    ]. Among the 710 (9 percent) patients with nonobstructive coronary artery disease, a primary end point occurred in 12 percent, including an event rate of 2 percent for death and MI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EARLY RISK STRATIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the increased use of coronary revascularization, patients with",
"    <span class=\"nowrap\">",
"     UA/NSTEMI",
"    </span>",
"    remain at risk for subsequent cardiac and arrhythmic events. As a result, ongoing risk stratification remains important. The following discussion will review the various features that have been applied in ongoing risk stratification. However, some of these results may",
"    <strong>",
"     not apply",
"    </strong>",
"    to current practice since many of the patients treated conservatively then would now undergo early revascularization. In addition, some of the findings, such as reduced LVEF and infarct location, apply to NSTEMI but not UA.",
"   </p>",
"   <p>",
"    High-risk patients generally are referred for angiography if it has not already been performed. Decisions for intermediate and low-risk patients usually are made after noninvasive testing.",
"   </p>",
"   <p>",
"    The importance of risk stratification prior to discharge is illustrated by the observation that, among all major cardiac events that occur in the first six weeks, approximately one-fourth occur after discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     TIMI risk score",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of data from the TIMI 11B and ESSENCE trials found seven variables to be independently predictive of outcome in patients with UA or an NSTEMI. These criteria were defined as the TIMI risk score. To calculate the score, a value of one is assigned when each variable was present and 0 when it was absent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &ge;65 years",
"     </li>",
"     <li>",
"      Presence of at least three risk factors for CHD",
"     </li>",
"     <li>",
"      Prior coronary stenosis of &ge;50 percent",
"     </li>",
"     <li>",
"      Presence of ST segment deviation on admission ECG",
"     </li>",
"     <li>",
"      At least two anginal episodes in prior 24 hours",
"     </li>",
"     <li>",
"      Elevated serum cardiac biomarkers",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      in prior seven days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    causing a worse outcome, it seems more likely that prior aspirin use is a marker for more underlying vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In terms of its specific effect, prior aspirin use appears to reduce the severity of the ACS (ie, less NSTEMI, more UA) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A higher TIMI risk score correlated significantly with increased numbers of events (all-cause mortality, new or recurrent MI, or severe recurrent ischemia requiring revascularization) at",
"    <strong>",
"     14 days",
"    </strong>",
"    &nbsp;(",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=see_link\">",
"     calculator 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Score of",
"      <span class=\"nowrap\">",
"       0/1",
"      </span>",
"      &mdash; 4.7 percent",
"     </li>",
"     <li>",
"      Score of 2 &mdash; 8.3 percent",
"     </li>",
"     <li>",
"      Score of 3 &mdash; 13.2 percent",
"     </li>",
"     <li>",
"      Score of 4 &mdash; 19.9 percent",
"     </li>",
"     <li>",
"      Score of 5 &mdash; 26.2 percent",
"     </li>",
"     <li>",
"      Score of",
"      <span class=\"nowrap\">",
"       6/7",
"      </span>",
"      &mdash; 40.9 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The TIMI risk score has been validated by applying it to the PRISM-PLUS database [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/23\">",
"     23",
"    </a>",
"    ] and to unselected patients seen at a district general hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar predictive value has been noted for postdischarge events at six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/19\">",
"     19",
"    </a>",
"    ] and for major cardiac events at 30 days in patients who have undergone PCI, which is now performed in most patients with a non-ST ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Not surprisingly, higher TIMI risk scores have been correlated with more severe angiographic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In an analysis from PRISM-PLUS, increasing TIMI risk scores from 0 to 2 (low risk) to 5 to 7 (high risk) were associated with progressive increases in the frequency of high-risk angiographic findings such as severe (&gt;70 percent) culprit stenosis (from 58 to 81 percent), multivessel disease (43 to 80 percent), visible thrombus (30 to 41 percent), and left main disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The TIMI risk score can also identify patients most likely to benefit from particular therapies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In TACTICS-TIMI 18, only patients at moderate to high risk (score &ge;3) benefited from an early invasive strategy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/12\">",
"       12",
"      </a>",
"      ]. The presence of biomarker elevation and ST segment deviation are two of the TIMI risk score variables. However, a later analysis from TACTICS-TIMI 18 showed that the degree of troponin elevation and magnitude of ST segment deviation were independent predictors of an adverse outcome and of benefit from an early invasive strategy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"       \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In PRISM-PLUS, only patients with a score &ge;4 benefited from the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In TIMI 11B and ESSENCE,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      was associated with better 14-day and six-week postdischarge outcomes compared to unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      ; these benefits were primarily seen in high-risk patients with risk scores &ge;4 and &ge;5, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link\">",
"       \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A potential limitation of the TIMI risk score in identifying patients at higher risk is that some patients who are troponin negative at baseline have an elevated value at 12 hours. A risk score has been devised and validated for identifying patients who are more likely to develop elevated troponins [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/28\">",
"     28",
"    </a>",
"    ]. The most important risk factors were any ST segment deviation, presentation less than eight hours from symptom onset, and no history of PCI. However, the score remained predictive in patients without ST segment deviation. The clinical utility of these observations is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     TIMI risk index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TIMI risk index (TRI) is a simpler model derived from the InTIME-II trial of thrombolytic therapy for ST elevation MI. It can be used simultaneously with the TIMI risk score. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=see_link&amp;anchor=H4#H4\">",
"     \"Risk stratification for cardiac events after acute ST elevation myocardial infarction\", section on 'TIMI risk index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The TRI is calculated from the following equation, using data obtained at presentation (",
"    <a class=\"graphic graphic_table graphicRef52542 \" href=\"UTD.htm?40/14/41195\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;TRI &nbsp;= &nbsp;(Heart rate &nbsp;x &nbsp;",
"    <span class=\"nowrap\">",
"     [age/10]",
"    </span>",
"    squared) &nbsp;&divide; &nbsp;systolic pressure",
"   </p>",
"   <p>",
"    When applied to over 337,000 patients with non-ST elevation MI in the National Registry of Myocardial Infarction (NRMI) in the United States, there was a graded relationship to in-hospital mortality, ranging from 1.0 to 34.4 percent from the lowest (0 to &lt;10) to the highest scores (&ge;80) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/30\">",
"     30",
"    </a>",
"    ]. Patients with a TRI &lt;30 were at low risk. Patients with higher risk indices were more often Killip class &gt;1 and had more frequent comorbidities such as heart failure, renal failure, and chronic obstructive pulmonary disease.",
"   </p>",
"   <p>",
"    A similar relationship was seen in over 150,000 patients with STEMI. The percent of patients at high risk (TRI &gt;60) was 10 percent in patients with NSTEMI, 14.1 percent with STEMI who were not reperfused, and only 2.1 percent with STEMI who were reperfused.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     ACCF/AHA classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association guidelines outlined a set of criteria for classification of patients with a non-ST elevation ACS into high, intermediate, and low risk groups (",
"    <a class=\"graphic graphic_table graphicRef55745 \" href=\"UTD.htm?6/60/7117\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/2,11\">",
"     2,11",
"    </a>",
"    ]. These criteria, incorporating history, clinical features, character of the pain, ECG findings, and cardiac biomarkers, were modified from a set of risk factors identified from extensive literature review and proposed originally by the Agency for Health Care Policy and Research (AHCPR) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The AHCPR version of these criteria was validated in a study of 457 patients presenting with acute cardiac ischemic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/32\">",
"     32",
"    </a>",
"    ]. Of this study population, 6, 54, and 40 percent were classified as low, intermediate, and high risk, respectively. At 30 days, the rates of cardiovascular morbidity (heart failure or ventricular arrhythmias) for the low, intermediate, and high risk groups were 0, 6, and 29 percent, respectively, with mortality rates of 0, 1.2, and 1.7 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     GRACE risk models",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TIMI risk score, while extensively validated as described above, is derived from two clinical trial databases. The GRACE registry, a global registry of ACS patients from 94 hospitals in 14 countries, developed two models to estimate the risk of",
"    <strong>",
"     in-hospital",
"    </strong>",
"    and",
"    <strong>",
"     six-month",
"    </strong>",
"    mortality among all patients with an ACS. This end point is different from the composite end point in the TIMI risk score of all-cause mortality, new or recurrent MI, or severe recurrent ischemia requiring revascularization.",
"   </p>",
"   <p>",
"    The in-hospital GRACE model was based upon data from 11,389 patients with either an STEMI or a non-ST elevation ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/33\">",
"     33",
"    </a>",
"    ]. This model was then validated based upon data from an additional 3972 patients from GRACE and 12,142 patients from the GUSTO IIb trial. Eight independent risk factors were found to account for almost 90 percent of the prognostic information:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age",
"     </li>",
"     <li>",
"      Killip class (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=see_link&amp;anchor=H6#H6\">",
"       \"Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction\", section on 'Killip class'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Systolic blood pressure",
"     </li>",
"     <li>",
"      Presence of ST segment deviation",
"     </li>",
"     <li>",
"      Cardiac arrest during presentation",
"     </li>",
"     <li>",
"      Serum creatinine concentration",
"     </li>",
"     <li>",
"      Presence of elevated serum cardiac biomarkers",
"     </li>",
"     <li>",
"      Heart rate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Point scores were assigned for each predictive factor and are added together to arrive at an estimate of the risk of in-hospital mortality. A nomogram was published with the GRACE risk model to allow calculation of the risk score. Software is available at",
"    <a class=\"external\" href=\"file://www.outcomes-umassmed.org/grace/acs_risk/acs_risk_content.html\">",
"     file://www.outcomes-umassmed.org/grace/acs_risk/acs_risk_content.html",
"    </a>",
"    to enable calculation of the GRACE risk score.",
"   </p>",
"   <p>",
"    Although designed to assess the risk of in-hospital mortality, this GRACE risk model also predicts mortality or recurrent MI at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/34\">",
"     34",
"    </a>",
"    ]. Its predictive value at one year is slightly greater than that for the TIMI risk score, which was designed to assess short-term mortality (",
"    <a class=\"graphic graphic_figure graphicRef67473 \" href=\"UTD.htm?30/55/31614\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The six-month model was based upon data from 15,007 patients and validated in a cohort of 7638 patients, all in the GRACE registry [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/35\">",
"     35",
"    </a>",
"    ]. The variables incorporated into this model include age, prior history of heart failure, prior history of myocardial infarction, resting heart rate, systolic blood pressure, ST-segment depression, initial serum creatinine concentration, elevated serum cardiac biomarkers, and performance of in-hospital PCI. The six-month mortality risk based upon this model can be calculated using the internet website",
"    <a class=\"external\" href=\"file://www.outcomes-umassmed.org/grace/\">",
"     www.outcomes-umassmed.org/grace/",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The GRACE database has also been used to develop a tool to identify low risk patients, called the \"freedom from events\" score, which includes many of the same variables as the GRACE risk score [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/36\">",
"     36",
"    </a>",
"    ]. The 30 percent of the population with lowest estimated risk had 0.5 percent in-hospital mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H183454700\">",
"    <span class=\"h2\">",
"     CHADS2 score",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the GRACE prediction model is well validated and is its use is recommended by multiple guideline organizations, its complexity makes it somewhat difficult to use in some clinical settings. The value of the CHADS2 score (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"UTD.htm?39/45/40668\">",
"     table 3",
"    </a>",
"    ), which is a well validated tool for predicting the risk of stroke in patients with atrial fibrillation, was evaluated in a study of more than 2300 patients with ACS (73 percent with",
"    <span class=\"nowrap\">",
"     UA/NSTEMI;",
"    </span>",
"    19 percent with AF) cared for between 1995 and 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/37\">",
"     37",
"    </a>",
"    ]. All-cause mortality at 10 years was strongly associated with the CHADS2 score in patients with and without AF. As expected, the more complex GRACE score provided a better prediction for short- and long-term mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=see_link&amp;anchor=H7#H7\">",
"     \"Risk of embolization in atrial fibrillation\", section on 'CHADS2 score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Patients at low risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk models addressed above included patients across the spectrum of risk. For lower risk patients with chest pain, but no ST segment deviation on the first ECG, and normal troponin levels, the risk of death or myocardial infarction may be as low as 6.7 percent at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/38\">",
"     38",
"    </a>",
"    ]. In a study of 646 patients with such characteristics, a risk score was constructed and included chest pain characteristics, the number of chest pain episodes in the 24 hours before presentation, the presence of insulin dependent diabetes mellitus, prior percutaneous coronary angioplasty, and age greater &ge;67 years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/38\">",
"     38",
"    </a>",
"    ]. The risk score was validated in a subsequent cohort and was found to be more predictive of outcome than the TIMI risk score in this low risk population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Individual risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding discussion has presented risk models for patients with a non-ST elevation ACS. Data on individual risk factors is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=see_link\">",
"     \"Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     LATE RISK STRATIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late risk stratification is performed before or sometimes after discharge. The main components are measurement of the left ventricular ejection fraction and, primarily in",
"    <strong>",
"     medically managed",
"    </strong>",
"    patients, stress testing to detect possible residual ischemia. The potential use of continuous ST segment monitoring is also discussed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Left ventricular function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of resting left ventricular function is an important part of risk stratification in patients with an acute non-ST elevation ACS. Patients with left ventricular systolic dysfunction have increased mortality at long-term follow-up and more than a 50 percent probability of having multivessel coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/7\">",
"     7",
"    </a>",
"    ]. The 2011 focused update of the American College of Cardiology",
"    <span class=\"nowrap\">",
"     Federation/American",
"    </span>",
"    Heart Association guidelines for the management of patients with unstable",
"    <span class=\"nowrap\">",
"     angina/non-ST",
"    </span>",
"    elevation myocardial infarction and the 2011 European Society of Cardiology guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation make strong recommendations for the evaluation of left ventricular ejection fraction (LVEF) after MI [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of a specific indication (eg, heart failure or suspected mechanical complication), the LVEF is usually measured before discharge. However, early measurements may be misleading, since improvement in LVEF, beginning within three days and largely complete by 14 days, is common in patients who either reperfuse spontaneously or undergo PCI, a presumed reflection, at least in part, of recovery from myocardial stunning [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8759?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical syndromes of stunned or hibernating myocardium\", section on 'Acute myocardial infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple imaging techniques for assessing left ventricular function are available and each has equivalent prognostic value in the post-MI patient. In general, echocardiography should be used for routine assessment of LVEF after a non-ST elevation ACS. Among patients who have had an NSTEMI, it has the added advantage of detecting other factors that can be associated with a worse prognosis such as diastolic dysfunction, concurrent right ventricular dysfunction, increased left atrial volume, mitral regurgitation, and a high wall motion score index, which reflects a more severe impairment in overall left ventricular systolic function [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/42-47\">",
"     42-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11369?source=see_link&amp;anchor=H22#H22\">",
"     \"Role of echocardiography in acute myocardial infarction\", section on 'Left ventricular systolic function'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11369?source=see_link&amp;anchor=H23#H23\">",
"     \"Role of echocardiography in acute myocardial infarction\", section on 'Left ventricular diastolic function'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=see_link\">",
"     \"Ischemic mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with an NSTEMI who have an interpretable ECG (ie, no left bundle branch block, paced rhythm, or left ventricular hypertrophy with strain pattern), the absence of an anterior infarction, a previous Q wave MI, or a history of HF predicts an LVEF of at least 40 percent (positive predictive value of 91 to 98 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The LVEF is variable among patients who do not fit the prediction rule, but may be preserved even in the setting of an anterior infarction pattern if reperfusion was achieved (mechanical, pharmacologic, or spontaneous).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Right ventricular function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long term impairment of right ventricular systolic function after MI is associated with a worse prognosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=see_link&amp;anchor=H20#H20\">",
"     \"Right ventricular myocardial infarction\", section on 'Long-term prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Stress testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress testing, usually with exercise, can be used to detect residual ischemia and to assess the exercise capacity needed for the cardiac rehabilitation exercise prescription. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Candidates for testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predischarge stress testing to detect residual ischemia is generally not performed in patients who have undergone PCI or CABG and have been",
"    <strong>",
"     fully",
"    </strong>",
"    revascularized (eg, single vessel disease and successful PCI) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/11\">",
"     11",
"    </a>",
"    ]. Such patients often undergo exercise testing a few weeks or more after discharge as part of a cardiac rehabilitation program or for activity counseling.",
"   </p>",
"   <p>",
"    In contrast, patients who have undergone partial revascularization or no revascularization are candidates for predischarge testing, but should be properly screened. Exercise testing appears to be safe if [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The patient has undergone in-hospital cardiac rehabilitation",
"     </li>",
"     <li>",
"      There have not been symptoms of heart failure or recurrent angina for 12 to 24 hours",
"     </li>",
"     <li>",
"      The electrocardiogram has been stable for 12 to 24 hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A stress test should be obtained before or after soon after discharge. The 2012 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association guidelines on unstable angina and non-ST elevation MI recognized the importance of early risk stratification [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/2\">",
"     2",
"    </a>",
"    ]. While the high-risk patient will often undergo an invasive study, lower-risk patients may undergo stress testing after being symptom free and stable for 12 to 24 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Stress protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriate stress protocol in patients who have not been completely revascularized varies with physician preferences, patient characteristics, and local laboratory expertise. Exercise ECG testing, which is most often performed, relies on both symptoms and objective changes on the ECG.",
"   </p>",
"   <p>",
"    In selected low risk patients (ie, without heart failure, arrhythmias, or angina), an early full Bruce (symptom limited) protocol has been safely completed as early as 24 hours or before discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. It provides a greater exercise stress and is more likely than a submaximal test to detect residual ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. However, the prognostic value of ST depression occurring at a higher work level is unproven and more data are needed to establish the safety and utility of this early protocol.",
"   </p>",
"   <p>",
"    Accurate stress ECG interpretation cannot be achieved in patients with baseline ECG abnormalities such as left bundle branch block, left ventricular hypertrophy with ST-T wave changes, ventricular preexcitation, or ventricular pacing. In such patients, either exercise radionuclide myocardial perfusion imaging (rMPI) or exercise echocardiography can be performed. Pharmacologic stress is required in patients who cannot exercise, although such modalities provide less information than exercise testing because they are not able to assess functional capacity (",
"    <a class=\"graphic graphic_algorithm graphicRef71324 \" href=\"UTD.htm?26/52/27470\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/2,53\">",
"     2,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=see_link\">",
"     \"Selecting the optimal cardiac stress test\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6678?source=see_link\">",
"     \"Radionuclide myocardial perfusion imaging in predischarge risk stratification of medically treated patients with non-ST elevation acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Stress testing in women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise ECG testing is associated with a higher false-positive rate in women than men, due at least in part to a lower pretest probability [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. However, among patients with a non-ST elevation ACS, exercise ECG risk scores appear to be as helpful for predicting prognosis in women as in men [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/56\">",
"     56",
"    </a>",
"    ] and recommendations for stress testing in women in this setting are generally similar to those in men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of silent ischemia discovered on stress testing after a non-ST elevation ACS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=see_link&amp;anchor=H16#H16\">",
"     \"Silent myocardial ischemia: Prognosis and therapy\", section on 'Post-MI ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Continuous electrocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Silent ischemia detected on continuous electrocardiography (continuous ST segment monitoring) is associated with an increased short-term risk of cardiovascular events. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=see_link&amp;anchor=H13#H13\">",
"     \"Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction\", section on 'Continuous ST segment monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar findings have been noted at longer term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. In the MERLIN-TIMI 36 trial, which compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/2/34854?source=see_link\">",
"     ranolazine",
"    </a>",
"    to placebo in patients with NSTEMI, 6355 patients underwent an average of six days of uninterrupted 2-lead (Holter) monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?2/43/2746/abstract/58\">",
"     58",
"    </a>",
"    ]. One or more transient ischemic episodes were noted in 20 percent of patients. After a median follow-up of almost one year, the patients with transient ischemic episodes had significant increases in the risk of cardiovascular death (7.7 versus 2.7 percent), MI (9.4 versus 5.0 percent) and recurrent ischemia (17.5 versus 12.3 percent). The association between transient ischemic episodes and symptomatic ischemia was not assessed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serial ECGs should be obtained once a day or with any change in symptoms. Continuous ECG monitoring is useful for establishing the occurrence of ST segment changes suggesting silent ischemia.",
"     </li>",
"     <li>",
"      Serum troponins and CK-MB should be drawn every eight hours over a 24 hour period.",
"     </li>",
"     <li>",
"      Other biomarkers, particularly in combination, can be considered for establishing prognosis (eg, CRP, BNP, and white blood cell count), although they are not yet routinely used for this purpose clinically.",
"     </li>",
"     <li>",
"      Prior to discharge, patients who have been",
"      <strong>",
"       medically treated",
"      </strong>",
"      should undergo noninvasive assessment for residual inducible ischemia. A firm recommendation about the choice of noninvasive test cannot be made. We perform symptom-limited exercise ECG testing in patients with normal resting ECGs who are not receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      and who are able to exercise on a treadmill. In all others, the choice between pharmacologic stress scintigraphy and stress echocardiography should be based upon the expertise available at the specific institution.",
"     </li>",
"     <li>",
"      In the absence of a specific indication (eg, heart failure or suspected mechanical complication), the left ventricular ejection fraction is usually measured before discharge and echocardiography is often the preferred method. If revascularization has been performed, some experts are comfortable waiting until after discharge to obtain an assessment of left ventricular function.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/1\">",
"      Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007; 28:2525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/2\">",
"      2012 Writing Committee Members, Jneid H, Anderson JL, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2012; 126:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/3\">",
"      Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation 1998; 98:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/4\">",
"      Furman MI, Dauerman HL, Goldberg RJ, et al. Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective. J Am Coll Cardiol 2001; 37:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/5\">",
"      Haim M, Behar S, Boyko V, et al. The prognosis of a first Q-wave versus non-Q-wave myocardial infarction in the reperfusion era. Am J Med 2000; 108:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/6\">",
"      Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002; 23:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/7\">",
"      Liebson PR, Klein LW. The non-Q wave myocardial infarction revisited: 10 years later. Prog Cardiovasc Dis 1997; 39:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/8\">",
"      Wang CH, Cherng WJ, Hua CC, Hung MJ. Prognostic value of dobutamine echocardiography in patients after Q-wave or non-Q-wave acute myocardial infarction. Am J Cardiol 1998; 82:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/9\">",
"      Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001; 103:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/10\">",
"      Lindahl B, Diderholm E, Lagerqvist B, et al. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol 2001; 38:979.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1 www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/12\">",
"      Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/13\">",
"      Cannon CP. Evidence-based risk stratification to target therapies in acute coronary syndromes. Circulation 2002; 106:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/14\">",
"      Robbins MA, Marso SP, Wolski K, et al. Chest pain--a strong predictor of adverse cardiac events following precutaneous intervention (from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial [EPISENT])]. Am J Cardiol 1999; 84:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/15\">",
"      Bugiardini R, Manfrini O, De Ferrari GM. Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography. Arch Intern Med 2006; 166:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/16\">",
"      Roe MT, Harrington RA, Prosper DM, et al. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Circulation 2000; 102:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/17\">",
"      Diver DJ, Bier JD, Ferreira PE, et al. Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial). Am J Cardiol 1994; 74:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/18\">",
"      Patel MR, Chen AY, Peterson ED, et al. Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative. Am Heart J 2006; 152:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/19\">",
"      Sabatine MS, McCabe CH, Morrow DA, et al. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. Am Heart J 2002; 143:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/20\">",
"      Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/21\">",
"      Borzak S, Cannon CP, Kraft PL, et al. Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia. Am J Cardiol 1998; 81:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/22\">",
"      Alexander JH, Harrington RA, Tuttle RH, et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol 1999; 83:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/23\">",
"      Morrow DA, Antman EM, Snapinn SM, et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. Eur Heart J 2002; 23:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/24\">",
"      Soiza RL, Leslie SJ, Williamson P, et al. Risk stratification in acute coronary syndromes--does the TIMI risk score work in unselected cases? QJM 2006; 99:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/25\">",
"      Kini AS, Lee PC, Mitre CA, et al. Prediction of outcome after percutaneous coronary intervention for the acute coronary syndrome. Am J Med 2003; 115:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/26\">",
"      Mega JL, Morrow DA, Sabatine MS, et al. Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Am Heart J 2005; 149:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/27\">",
"      Sabatine MS, Morrow DA, McCabe CH, et al. Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction. Am Heart J 2006; 151:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/28\">",
"      Januzzi JL Jr, Newby LK, Murphy SA, et al. Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. Am Heart J 2006; 151:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/29\">",
"      Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet 2001; 358:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/30\">",
"      Wiviott SD, Morrow DA, Frederick PD, et al. Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction. J Am Coll Cardiol 2006; 47:1553.",
"     </a>",
"    </li>",
"    <li>",
"     Braunwald, E, Mark, D, Jones, R, et al. Unstable Angina: Diagnosis and Management: Clinical Practice Guideline Number 10. Rockville, Md: Agency for Health Care Policy and Research; 1994. Publication 94-0602.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/32\">",
"      Katz DA, Griffith JL, Beshansky JR, Selker HP. The use of empiric clinical data in the evaluation of practice guidelines for unstable angina. JAMA 1996; 276:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/33\">",
"      Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/34\">",
"      de Ara&uacute;jo Gon&ccedil;alves P, Ferreira J, Aguiar C, Seabra-Gomes R. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J 2005; 26:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/35\">",
"      Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004; 291:2727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/36\">",
"      Brieger D, Fox KA, Fitzgerald G, et al. Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart 2009; 95:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/37\">",
"      Po&ccedil;i D, Hartford M, Karlsson T, et al. Role of the CHADS2 score in acute coronary syndromes: risk of subsequent death or stroke in patients with and without atrial fibrillation. Chest 2012; 141:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/38\">",
"      Sanchis J, Bod&iacute; V, N&uacute;&ntilde;ez J, et al. New risk score for patients with acute chest pain, non-ST-segment deviation, and normal troponin concentrations: a comparison with the TIMI risk score. J Am Coll Cardiol 2005; 46:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/39\">",
"      Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 57:e215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/40\">",
"      Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:2999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/41\">",
"      Solomon SD, Glynn RJ, Greaves S, et al. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Intern Med 2001; 134:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/42\">",
"      Nijland F, Kamp O, Karreman AJ, et al. Prognostic implications of restrictive left ventricular filling in acute myocardial infarction: a serial Doppler echocardiographic study. J Am Coll Cardiol 1997; 30:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/43\">",
"      M&oslash;ller JE, S&oslash;ndergaard E, Poulsen SH, Egstrup K. Pseudonormal and restrictive filling patterns predict left ventricular dilation and cardiac death after a first myocardial infarction: a serial color M-mode Doppler echocardiographic study. J Am Coll Cardiol 2000; 36:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/44\">",
"      Zornoff LA, Skali H, Pfeffer MA, et al. Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. J Am Coll Cardiol 2002; 39:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/45\">",
"      Moller JE, Hillis GS, Oh JK, et al. Left atrial volume: a powerful predictor of survival after acute myocardial infarction. Circulation 2003; 107:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/46\">",
"      Grigioni F, Enriquez-Sarano M, Zehr KJ, et al. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 2001; 103:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/47\">",
"      M&oslash;ller JE, Hillis GS, Oh JK, et al. Wall motion score index and ejection fraction for risk stratification after acute myocardial infarction. Am Heart J 2006; 151:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/48\">",
"      Silver MT, Rose GA, Paul SD, et al. A clinical rule to predict preserved left ventricular ejection fraction in patients after myocardial infarction. Ann Intern Med 1994; 121:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/49\">",
"      Tobin K, Stomel R, Harber D, et al. Validation in a community hospital setting of a clinical rule to predict preserved left ventricular ejection fraction in patients after myocardial infarction. Arch Intern Med 1999; 159:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/50\">",
"      Senaratne MP, Smith G, Gulamhusein SS. Feasibility and safety of early exercise testing using the Bruce protocol after acute myocardial infarction. J Am Coll Cardiol 2000; 35:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/51\">",
"      Juneau M, Colles P, Th&eacute;roux P, et al. Symptom-limited versus low level exercise testing before hospital discharge after myocardial infarction. J Am Coll Cardiol 1992; 20:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/52\">",
"      Jain A, Myers GH, Sapin PM, O'Rourke RA. Comparison of symptom-limited and low level exercise tolerance tests early after myocardial infarction. J Am Coll Cardiol 1993; 22:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/53\">",
"      Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/54\">",
"      Kwok Y, Kim C, Grady D, et al. Meta-analysis of exercise testing to detect coronary artery disease in women. Am J Cardiol 1999; 83:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/55\">",
"      Alexander KP, Shaw LJ, Shaw LK, et al. Value of exercise treadmill testing in women. J Am Coll Cardiol 1998; 32:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/56\">",
"      S&auml;fstr&ouml;m K, Lindahl B, Swahn E. Risk stratification in unstable coronary artery disease--exercise test and troponin T from a gender perspective. FRISC-Study Group. Fragmin during InStability in Coronary artery disease. J Am Coll Cardiol 2000; 35:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/57\">",
"      Goodman SG, Barr A, Sobtchouk A, et al. Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy. J Am Coll Cardiol 2000; 36:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/43/2746/abstract/58\">",
"      Scirica BM, Morrow DA, Budaj A, et al. Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol 2009; 53:1411.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 76 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-2733C36ADC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_43_2746=[""].join("\n");
var outline_f2_43_2746=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IMMEDIATE HIGH-RISK PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EARLY INVASIVE VERSUS CONSERVATIVE STRATEGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Absence of significant coronary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EARLY RISK STRATIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TIMI risk score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TIMI risk index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ACCF/AHA classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GRACE risk models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H183454700\">",
"      CHADS2 score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Patients at low risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Individual risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      LATE RISK STRATIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Left ventricular function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Right ventricular function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Stress testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Candidates for testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Timing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Stress protocol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Stress testing in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Continuous electrocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/76\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/76|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?26/52/27470\" title=\"algorithm 1\">",
"      Choice stress test modality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/76|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/55/31614\" title=\"figure 1\">",
"      TIMI risk score for non-ST elevation ACS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/76|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/14/41195\" title=\"table 1\">",
"      TIMI risk index mortality MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/60/7117\" title=\"table 2\">",
"      Risk of death or MI in UA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/45/40668\" title=\"table 3\">",
"      CHADS2 score and thromboembolic risk with and without warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=related_link\" title=\"calculator 1\">",
"      Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for unstable angina or non ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=related_link\">",
"      Classification of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8759?source=related_link\">",
"      Clinical syndromes of stunned or hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=related_link\">",
"      Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=related_link\">",
"      Intracoronary stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18297?source=related_link\">",
"      Ischemic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37930?source=related_link\">",
"      Long-term outcome after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=related_link\">",
"      Performance of exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6678?source=related_link\">",
"      Radionuclide myocardial perfusion imaging in predischarge risk stratification of medically treated patients with non-ST elevation acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=related_link\">",
"      Right ventricular myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=related_link\">",
"      Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=related_link\">",
"      Risk of embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=related_link\">",
"      Risk stratification for cardiac events after acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11369?source=related_link\">",
"      Role of echocardiography in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=related_link\">",
"      Selecting the optimal cardiac stress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=related_link\">",
"      Silent myocardial ischemia: Prognosis and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_43_2747="Varicocele grading";
var content_f2_43_2747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Grading of varicoceles",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1\">",
"        Size",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Small",
"       </td>",
"       <td>",
"        Palpable only with valsalva maneuver",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Nonvisible on inspection, but palpable upon standing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Large",
"       </td>",
"       <td>",
"        Visible on gross inspection",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_43_2747=[""].join("\n");
var outline_f2_43_2747=null;
var title_f2_43_2748="Features of bleeding disorders";
var content_f2_43_2748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical manifestations of bleeding disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Bleeding symptoms",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Bleeding disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Platelet defects (qualitative or quantitative)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Clotting factor deficiencies (eg,&nbsp; factor VIII or factor IX deficiencies)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Overview of bleeding events",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <p>",
"         Mucocutaneous bleeding",
"         <br/>",
"         &nbsp;&nbsp;&nbsp; (oral cavity, nasal, gastrointestinal, and genitourinary sites)",
"        </p>",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Deep tissue bleeding",
"        <br/>",
"        &nbsp;&nbsp;&nbsp; (including joints and muscles)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Excessive bleeding after minor cuts",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Not usually",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Petechiae",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"       <td>",
"        Uncommon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ecchymoses",
"       </td>",
"       <td>",
"        Generally small and superficial; may be significant, depending upon the defect or degree of thrombocytopenia",
"       </td>",
"       <td>",
"        May develop large subcutaneous and soft tissue hematomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemarthroses, muscle hematomas",
"       </td>",
"       <td>",
"        Uncommon",
"       </td>",
"       <td>",
"        Common in severe deficiency states or in association with injury in those with mild to moderate deficiency states",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bleeding with invasive procedures, including surgery",
"       </td>",
"       <td>",
"        Often immediate, with degree of bleeding dependent upon the severity of the defect, ranging from none (eg, mild degrees of thrombocytopenia or mild platelet function defect) to mild to severe (eg, Glanzmann thrombasthenia)",
"       </td>",
"       <td>",
"        May be associated either with procedural bleeding or delayed bleeding, depending upon the type and severity of the defect",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_43_2748=[""].join("\n");
var outline_f2_43_2748=null;
var title_f2_43_2749="6As for smoking prevention and cessation in children";
var content_f2_43_2749=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Six \"A's\" to prevent smoking initiation or support smoking cessation among adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Intervention",
"      </td>",
"      <td class=\"subtitle1\">",
"       Technique",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anticipate",
"      </td>",
"      <td>",
"       Routinely ask parents about smoking and discuss the health effects of tobacco use. Discuss the possibility of smoking onset in pre-teen and adolescent children, and the need for consistent messages from parents to prevent smoking initiation.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ask",
"      </td>",
"      <td>",
"       For all adolescents at every visit, ask about tobacco use without the parents in the room. For pre-teen children also inquire about tobacco use in an age-appropriate manner (eg, whether they have ever \"tried\" smoking or thought about trying). Also inquire about tobacco use among peers, as this may predict smoking initiation.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       Advise",
"      </td>",
"      <td>",
"       Strongly urge all tobacco users to quit in a clear, strong, personalized manner. Advise all non-users to remain tobacco-free.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Advice should be:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Clear - \"I think it is important for you to quit smoking now and I can help you.\" \"Cutting down is not enough.\" \"If you wait until you feel bad effects of smoking it will be too late.\"",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Strong - \"As your doctor, I want you to know that quitting smoking is the most important thing you can do to protect your health now and in the future. I will help you quit.\"",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Personalized - Tie tobacco use to current and future health and athletic performance, its social and economic costs, motivation level/readiness to quit, and the impact of tobacco use on siblings and others in the household. Remind parents of their responsibility as role models.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       Assess",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Determine the patient's willingness to quit smoking within the next 30 days:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       If the patient is willing to make a quit attempt at this time, provide assistance.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       If the patient will participate in an intensive treatment, deliver such a treatment or refer to an intensive intervention.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       If the patient clearly states he or she is unwilling to make a quit attempt at this time, provide a motivational intervention.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       If the patient is a member of a special population (eg, pregnant smoker, racial or ethnic minority), consider providing additional information relevant to this population.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Assist",
"      </td>",
"      <td>",
"       Provide aid for the patient to quit (eg, set a quit date, provide counseling and self-help materials, refer to a quit line).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Arrange",
"      </td>",
"      <td>",
"       Schedule follow-up contact, either in person or by telephone. Follow-up contact should occur soon after the quit date, preferably during the first week. A second follow-up contact is recommended within the first month. Schedule further follow-up contacts as indicated.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Congratulate success during each follow-up. If tobacco use has occurred, review circumstances and elicit recommitment to total abstinence. Remind the patient that a lapse can be used as a learning experience. Identify problems already encountered and anticipate challenges in the immediate future. Assess pharmacotherapy use and problems. Consider use or referral to more intensive treatment.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Fiore, MC, Bailey, WC, Cohen, SJ, et al. Treating Tobacco Use and Dependence. Quick Reference Guide for Clinicians. Rockville, MD: US Department of Health and Human Services. Public Health Service. October 2000 and Sims, TH. Pediatrics 2009; 124:e1045.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_43_2749=[""].join("\n");
var outline_f2_43_2749=null;
var title_f2_43_2750="TC regimen for breast cancer";
var content_f2_43_2750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Docetaxel (Taxotere) and cyclophosphamide (TC) adjuvant chemotherapy for breast cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        <p>",
"         Cycle length: 21 days.",
"        </p>",
"        Total cycles: 4.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Docetaxel",
"        </strong>",
"       </td>",
"       <td>",
"        75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL normal saline (NS) or 5 percent dextrose in water (D5W) to a final concentration of 0.3 to 0.74 mg/mL, and administer over 60 minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cyclophosphamide",
"        </strong>",
"       </td>",
"       <td>",
"        600 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 to 500 mL NS or D5W and administer over 30 to 60 minutes after docetaxel.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        Patients receiving cyclophosphamide should maintain adequate oral hydration (2 to 3 L/day during treatment and one to two days thereafter) and void frequently to reduce the risk of hemorrhagic cystitis",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MODERATE (between 30 and 90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Premedication with dexamethasone 8 mg twice daily for three days, starting one day prior to docetaxel administration, is recommended",
"        <sup>",
"         [3]",
"        </sup>",
"        . Glucocorticoid pretreatment also reduces the incidence of docetaxel-induced fluid retention. If a severe infusion reaction to docetaxel occurs (chest tightness, wheezing, hypoxia, loss of consciousness), docetaxel should be immediately discontinued. However, if the reaction is minor (eg, flushing or localized skin reaction), the infusion can be continued or it can be temporarily interrupted, and restarted at 50 percent of the initial rate once symptoms have resolved. The rate can then be increased if tolerated. Management of infusion reactions and issues related to rechallenge are discussed separately. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Docetaxel and cyclophosphamide are both classified as irritants. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Not generally recommended, but consider use for patients over the age of 65. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver dysfunction:",
"        </strong>",
"        Docetaxel should not be administered to patients with a serum bilirubin above the ULN or to patients with transaminase elevations &gt;1.5 times ULN in conjunction with alkaline phosphatase &gt;2.5 times ULN. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline renal dysfunction:",
"        </strong>",
"        Dose adjustment is not necessary for docetaxel in renal impairment. The need for cyclophosphamide dose reduction in renal insufficiency is controversial. Refer to UpToDate topic on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count on day 1 prior to each cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Serum electrolytes and liver and renal function tests every two weeks prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Docetaxel should only be administered if the absolute neutrophil count is greater than 1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        . A 25 percent dose reduction of docetaxel is recommended for subsequent cycles in patients who develop severe prolonged neutropenia (less than 500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        lasting seven days or more), febrile neutropenia, or a grade 4 infection (ie, an infection with life-threatening consequences)",
"        <sup>",
"         [3]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for hepatic dysfunction:",
"        </strong>",
"        Docetaxel dose reduction may be needed for patients who develop significant alterations in transaminases and alkaline phosphatase during therapy. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Cutaneous, mucosal, and neurologic toxicity:",
"        </strong>",
"        For severe or cumulative cutaneous reactions (erythema and desquamation), grade 3 or 4 stomatitis, or moderate neurosensory signs and/or symptoms, the dose of docetaxel should be reduced from 75 to 60 mg/m",
"        <sup>",
"         2[3]",
"        </sup>",
"        . If toxicity persists, treatment should be discontinued.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; ULN: upper limit of normal; CBC: complete blood count.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Jones SE, et al. J Clin Oncol 2006; 24:5381.",
"      </li>",
"      <li>",
"       Cytoxan (cyclophosphamide) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 20, 2011).",
"      </li>",
"      <li>",
"       Taxotere (docetaxel) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 20, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_43_2750=[""].join("\n");
var outline_f2_43_2750=null;
var title_f2_43_2751="Subglottic edema";
var content_f2_43_2751=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subglottic edema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral view demonstrates ballooning of the supralaryngeal structures and marked narrowing of the subglottic trachea secondary to subglottic edema. This finding cannot be simulated in the normal child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Department of Diagnostic Imaging, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_43_2751=[""].join("\n");
var outline_f2_43_2751=null;
